




# Bacterial Catabolism of $\beta$ -Hydroxypropiovanillone and $\beta$ -Hydroxypropiosyringone Produced in the Reductive Cleavage of Arylglycerol- $\beta$ -Aryl Ether in Lignin

Yudai Higuchi,<sup>a</sup> Shogo Aoki,<sup>a</sup> Hiroki Takenami,<sup>a</sup> Naofumi Kamimura,<sup>a</sup> Kenji Takahashi,<sup>a</sup> Shojiro Hishiyama,<sup>b</sup> Christopher S. Lancefield,<sup>c</sup> O. Stephen Ojo,<sup>c</sup> Yoshihiro Katayama,<sup>d</sup> Nicholas J. Westwood,<sup>c</sup>  Eiji Masai<sup>a</sup>

<sup>a</sup>Department of Bioengineering, Nagaoka University of Technology, Nagaoka, Niigata, Japan

<sup>b</sup>Forestry and Forest Products Research Institute, Tsukuba, Ibaraki, Japan

<sup>c</sup>School of Chemistry and Biomedical Sciences Research Complex, University of St Andrews and EaStCHEM, North Haugh, St Andrews, Fife, United Kingdom

<sup>d</sup>College of Bioresource Sciences, Nihon University, Fujisawa, Kanagawa, Japan

**ABSTRACT** *Sphingobium* sp. strain SYK-6 converts four stereoisomers of arylglycerol- $\beta$ -guaiacyl ether into achiral  $\beta$ -hydroxypropiovanillone (HPV) via three stereospecific reaction steps. Here, we determined the HPV catabolic pathway and characterized the HPV catabolic genes involved in the first two steps of the pathway. In SYK-6 cells, HPV was oxidized to vanilloyl acetic acid (VAA) via vanilloyl acetaldehyde (VAL). The resulting VAA was further converted into vanillate through the activation of VAA by coenzyme A. A syringyl-type HPV analog,  $\beta$ -hydroxypropiosyringone (HPS), was also catabolized via the same pathway. SLG\_12830 (*hpvZ*), which belongs to the glucose-methanol-choline oxidoreductase family, was isolated as the HPV-converting enzyme gene. An *hpvZ* mutant completely lost the ability to convert HPV and HPS, indicating that *hpvZ* is essential for the conversion of both the substrates. HpvZ produced in *Escherichia coli* oxidized both HPV and HPS and other 3-phenyl-1-propanol derivatives. HpvZ localized to both the cytoplasm and membrane of SYK-6 and used ubiquinone derivatives as electron acceptors. Thirteen gene products of the 23 aldehyde dehydrogenase (ALDH) genes in SYK-6 were able to oxidize VAL into VAA. Mutant analyses suggested that multiple ALDH genes, including SLG\_20400, contribute to the conversion of VAL. We examined whether the genes encoding feruloyl-CoA synthetase (*ferA*) and feruloyl-CoA hydratase/lyase (*ferB* and *ferB2*) are involved in the conversion of VAA. Only FerA exhibited activity toward VAA; however, disruption of *ferA* did not affect VAA conversion. These results indicate that another enzyme system is involved in VAA conversion.

**IMPORTANCE** Cleavage of the  $\beta$ -aryl ether linkage is the most essential process in lignin biodegradation. Although the bacterial  $\beta$ -aryl ether cleavage pathway and catabolic genes have been well documented, there have been no reports regarding the catabolism of HPV or HPS, the products of cleavage of  $\beta$ -aryl ether compounds. HPV and HPS have also been found to be obtained from lignin by chemoselective catalytic oxidation by 2,3-dichloro-5,6-dicyano-1,4-benzoquinone/*tert*-butyl nitrite/O<sub>2</sub>, followed by cleavage of the  $\beta$ -aryl ether with zinc. Therefore, value-added chemicals are expected to be produced from these compounds. In this study, we determined the SYK-6 catabolic pathways for HPV and HPS and identified the catabolic genes involved in the first two steps of the pathways. Since SYK-6 catabolizes HPV through 2-pyrone-4,6-dicarboxylate, which is a building block for functional polymers, characterization of HPV catabolism is important not only for understanding the bacterial lignin catabolic system but also for lignin utilization.

Received 5 December 2017 Accepted 19 January 2018

Accepted manuscript posted online 26 January 2018

**Citation** Higuchi Y, Aoki S, Takenami H, Kamimura N, Takahashi K, Hishiyama S, Lancefield CS, Ojo OS, Katayama Y, Westwood NJ, Masai E. 2018. Bacterial catabolism of  $\beta$ -hydroxypropiovanillone and  $\beta$ -hydroxypropiosyringone produced in the reductive cleavage of arylglycerol- $\beta$ -aryl ether in lignin. *Appl Environ Microbiol* 84:e02670-17. <https://doi.org/10.1128/AEM.02670-17>.

**Editor** Rebecca E. Parales, University of California, Davis

**Copyright** © 2018 American Society for Microbiology. All Rights Reserved.


Address correspondence to Eiji Masai, [emasai@vos.nagaokaut.ac.jp](mailto:emasai@vos.nagaokaut.ac.jp).

**KEYWORDS** *Sphingobium*, lignin, beta-aryl ether, glucose-methanol-choline oxidoreductase, aldehyde dehydrogenase

Lignin, one of the major components of plant cell walls, is a complex phenolic heteropolymer produced from hydroxycinnamyl alcohols by radical coupling (1, 2). Lignin is the second most abundant bioresource on earth after cellulose and is expected to be used as an industrial raw material. However, the current industrial applications of lignin are limited to low-value applications such as the production of solid fuels and concrete additives (3, 4). On the other hand, it has been reported that the building blocks for functional polymers, such as 2-pyrone-4,6-dicarboxylic acid (5–7), *cis,cis*-muconic acid (8–10), and medium-chain-length polyhydroxyalkanoic acid (11), can be obtained from lignin-derived aromatic compounds such as vanillic acid, vanillin, ferulic acid, and *p*-coumaric acid through microbial catabolism. Therefore, the production of value-added chemicals from lignin through transformations systems that consist of chemical lignin decomposition and microbial catabolism of lignin-derived aromatics has attracted attention.

$\beta$ -Aryl ether is the most abundant linkage in lignin, comprising 45 to 50% of all linkages in softwood lignin and 60 to 62% in hardwood lignin (4). Accordingly, degradation of this structure is considered a crucial step in lignin biodegradation.  $\beta$ -Aryl ether-type biaryls have two distinct isomeric forms, *erythro* and *threo*, each of which has enantiomeric forms (12). To date, the whole picture of the enzyme system for the cleavage of  $\beta$ -aryl ether in *Sphingobium* sp. strain SYK-6 has been determined (13). SYK-6 is able to degrade all the stereoisomers of the  $\beta$ -aryl ether-type biaryl, guaiacylglycerol- $\beta$ -guaiacyl ether (GGE). In SYK-6 cells, four stereoisomers of GGE are converted to two enantiomers of  $\alpha$ -(2-methoxyphenoxy)- $\beta$ -hydroxypropiovanillone (MPPHV) through the oxidation of the GGE  $\alpha$ -carbon atom catalyzed by  $\alpha$ -dehydrogenases (LigD, LigL, and LigN) (Fig. 1) (14). LigD oxidizes ( $\alpha R, \beta S$ )-GGE and ( $\alpha R, \beta R$ )-GGE into ( $\beta S$ )-MPPHV and ( $\beta R$ )-MPPHV, respectively, while LigL/LigN converts ( $\alpha S, \beta R$ )-GGE and ( $\alpha S, \beta S$ )-GGE into ( $\beta R$ )-MPPHV and ( $\beta S$ )-MPPHV, respectively (14). The ether linkage of the resulting MPPHV is cleaved by enantioselective glutathione *S*-transferases (GSTs)—LigF, LigE, and LigP—to produce  $\alpha$ -glutathionyl- $\beta$ -hydroxypropiovanillone (GS-HPV) and guaiacol via nucleophilic attack of glutathione on the MPPHV  $\beta$ -carbon atom (15, 16). LigF and LigE/LigP attack ( $\beta S$ )-MPPHV and ( $\beta R$ )-MPPHV to produce ( $\beta R$ )-GS-HPV and ( $\beta S$ )-GS-HPV, respectively. Another GST, LigG, catalyzes the cleavage of the thioether linkage in ( $\beta R$ )-GS-HPV by transferring glutathione of ( $\beta R$ )-GS-HPV to another glutathione molecule to produce HPV and glutathione disulfide (15, 17). On the other hand, LigG had little to no activity with ( $\beta S$ )-GS-HPV, suggesting involvement of an alternative GST in the conversion of ( $\beta S$ )-GS-HPV (15, 18). Recently, further detailed biochemical characterization of the  $\beta$ -aryl ether catabolic enzymes of SYK-6 and their orthologs in other bacterial strains, and structural analyses of LigD, LigL, LigE, LigF, and LigG have been performed (17–29). In addition, *Erythrobacter* sp. strain SG61-1L and *Novosphingobium* sp. strain MBES04, which are capable of cleaving  $\beta$ -aryl ether, have recently been isolated, and similar enzyme systems have been characterized (23, 24).

Although many investigations of the cleavage of  $\beta$ -aryl ether have been performed, there are no reports on the characterization of the catabolism of HPV, the product of the cleavage of  $\beta$ -aryl ether. Therefore, in order to understand bacterial  $\beta$ -aryl ether catabolism, it is essential to elucidate the HPV catabolic system. Recently, the production of HPV and  $\beta$ -hydroxypropiosyringone (HPS; an intermediate metabolite of syringyl-type  $\beta$ -aryl ether) from lignin has been attempted through biological and chemical processes for the purpose of obtaining phenolic monomers from lignin (27, 30). Ohta et al. reported that HPV and HPS could be obtained from milled wood lignin from Japanese cedar (*Cryptomeria japonica*) and *Eucalyptus globulus* after reactions with MBES04 enzymes (27). Lancefield et al. reported an isolation method for HPV and HPS from Birch lignin via catalytic oxidation of the  $\beta$ -aryl ether linkage in lignin, followed by




**FIG 1** Proposed catabolic pathway of arylglycerol- $\beta$ -aryl ether in *Spingobium* sp. strain SYK-6. The pathway for both guaiacyl (R = H) and syringyl (R = OCH<sub>3</sub>)-type  $\beta$ -aryl ether compounds is shown. Enzymes: LigD, LigL, and LigN,  $\text{C}\alpha$ -dehydrogenases; LigF, LigE, and LigP,  $\beta$ -etherases; LigG, glutathione S-transferase; HpvZ, HPV oxidase; ALDHs, aldehyde dehydrogenases. Abbreviations: GGE, guaiacylglycerol- $\beta$ -guaiacyl ether; MPPHV,  $\alpha$ -(2-methoxyphenoxy)- $\beta$ -hydroxypropiovanillone; GS-HPV,  $\alpha$ -glutathionyl- $\beta$ -hydroxypropiovanillone; HPV,  $\beta$ -hydroxypropiovanillone; HPS,  $\beta$ -hydroxypropiosyringone; VAL, vanilloyl acetaldehyde; SAL, 3-(4-hydroxy-3,5-dimethoxyphenyl)-3-oxopropanal; VAA, vanilloyl acetic acid; SAA, 3-(4-hydroxy-3,5-dimethoxyphenyl)-3-oxopropanoic acid; CoA, coenzyme A; VAA-CoA, CoA derivative of VAA.

zinc-mediated cleavage of the ether bonds (30). By combining these decomposition methods with microbial catabolism of HPV and HPS, the development of a production system for value-added chemicals from lignin is expected.

In the present study, we determined the catabolic pathway of HPV and HPS in SYK-6 and characterized the genes involved in the first two steps of the pathway.

## RESULTS AND DISCUSSION

**Determination of the pathway for the catabolism of HPV and HPS in *Spingobium* sp. strain SYK-6.** In order to determine the catabolic pathway of HPV in SYK-6, intermediate metabolites generated during the incubation of HPV with resting cells of SYK-6 were identified. Resting cells of SYK-6 grown in Wx minimal medium (31) containing 10 mM sucrose, 10 mM glutamate, 0.13 mM methionine, and 10 mM proline (Wx-SEMP) were incubated with 1 mM HPV for 6 h, and the reaction mixtures were analyzed by high-performance liquid chromatography-mass spectrometry (HPLC-MS). This analysis indicated that HPV was converted into compound I with a retention time of 3.1 min (Fig. 2B). Based on a comparison of the retention time and the  $m/z$  value of the deprotonated ion of compound I to those of the authentic sample, this compound was identified as vanillic acid (molecular weight [MW], 168) (Fig. 2C and see Fig. S1A and B in the supplemental material). Next, a cell extract (>10 kDa) of SYK-6 cells grown in Wx-SEMP was incubated with 200  $\mu\text{M}$  HPV for 24 h. HPLC-MS analysis of the reaction mixture showed that HPV was converted into compound II with a retention time of 2.9 min (Fig. 2E). Positive electrospray ionization (ESI)-MS analysis of compound II showed a major fragment at  $m/z$  298 (Fig. 2F). Based on the MW deduced from the major fragment ion and additives in the reaction mixture, compound II was identified as



**FIG 2** HPLC-MS analysis of HPV metabolites. Resting cells of SYK-6 ( $OD_{600}$  of 5.0) and SYK-6 cell extracts ( $>10$  kDa; 500  $\mu$ g of protein/ml) were incubated with 1 mM HPV (A and B) and 200  $\mu$ M HPV (D and E), respectively. The same cell extracts ( $>10$  kDa) were incubated with HPV in the presence of 500  $\mu$ M NAD<sup>+</sup> (G and H) and in the presence of 500  $\mu$ M NAD<sup>+</sup> + 2 mM CoA + 2.5 mM MgSO<sub>4</sub> + 2.5 mM ATP (J and K). Portions of the reaction mixtures were collected at the start (A and D) and after 2 h (G and J), 6 h (B), and 24 h (E, H, and K) of incubation and then analyzed by HPLC. The ESI-MS spectra of compounds I (negative mode), II (positive mode), III (negative mode), and IV (positive mode) are shown in panels C, F, I, and L, respectively. The asterisk (\*) in panel I indicates an unidentified MS fragment that appeared between retention times of 2.0 and 7.0 min in the HPLC chromatogram (H).

an imine derivative of vanilloyl acetaldehyde (VAL), 2-((3-hydroxy-3-(4-hydroxy-3-methoxyphenyl)allylidene)amino)-2-(hydroxymethyl)propane-1,3-diol or its oxazolidine product (VAL-Tris; MW, 297; see Fig. S1C and D in the supplemental material). It is known that some aldehyde substrates, such as glyceraldehyde 3-phosphate, acetaldehyde, and benzaldehyde, react with Tris to form imine product, which is then trapped


by one of the free hydroxyl groups forming an oxazolidine product (32). Furthermore, Fukuzumi et al. attempted to synthesize VAL by Claisen-Wislicenus hydroxymethylene condensation between acetovanillone and ethyl formate in the presence of metallic sodium; however, *cis*-vanilloyl vinyl alcohol, a tautomer of VAL, was obtained as a major product (33). It was thought that VAL had five possible tautomers, and the form of hydroxyl vinyl ketone structure (vanilloyl vinyl alcohol) was stable (33). These observations suggested that VAL-Tris (imine product) was produced from HPV through oxidation of C $\gamma$ -alcohol catalyzed by the SYK-6 cell extract to generate VAL and to result in the isomerization of VAL and condensation between a VAL isomer and Tris in the reaction buffer. VAL-Tris (imine product) was then possibly converted to the oxazolidine product.

When a SYK-6 cell extract (>10 kDa) was incubated with 200  $\mu$ M HPV in the presence of 500  $\mu$ M NAD<sup>+</sup> for 2 h, an accumulation of compound III with a retention time of 4.7 min was observed (Fig. 2G). Negative ESI-MS analysis of compound III showed fragments at *m/z* 209 and 165 (Fig. 2I). Since these fragments seemed to represent the deprotonated ion and its decarboxylated ion, respectively, compound III was identified as vanilloyl acetic acid (VAA; MW, 210; see Fig. S1E and F in the supplemental material). VAL seems to be transformed to VAA by NAD<sup>+</sup>-dependent aldehyde dehydrogenase(s) (ALDHs) (Fig. 1). In addition, when the same reaction mixture was incubated for 24 h, compound IV with a retention time of 5.8 min was generated (Fig. 2H). A comparison of the retention time and *m/z* value of the protonated ion with those of the authentic sample indicated that compound IV was acetovanillone (MW, 166; Fig. 2L and see Fig. S1G and H in the supplemental material). Previously, Niwa and Saburi reported that VAA was spontaneously decarboxylated to acetovanillone (Fig. 1) (34).

Because lignin-derived aromatic acids such as ferulate, *p*-coumarate, and caffeate are catabolized via coenzyme A (CoA)-dependent pathways, we predicted that VAA is catabolized through its C $\gamma$  activation by CoA (35–39). A SYK-6 cell extract (>10 kDa) was therefore incubated with 200  $\mu$ M HPV in the presence of 500  $\mu$ M NAD<sup>+</sup>, 2 mM CoA, 2.5 mM MgSO<sub>4</sub>, and 2.5 mM ATP. After incubation for 2 h, a decrease in HPV and an accumulation of VAA (compound III) were observed (Fig. 2J). After further incubation for 24 h, vanillic acid (compound I) and acetovanillone (compound IV) were observed (Fig. 2K). Vanillic acid was generated only when CoA, ATP, and MgSO<sub>4</sub> were present. This result strongly suggested that VAA was converted to vanillate through the CoA derivative of VAA (Fig. 1).

Similarly, we examined the SYK-6 catabolic pathway of HPS. Resting SYK-6 cells grown in Wx-SEMP were incubated with 1 mM HPS for 4 h, and the reaction mixtures were analyzed by HPLC-MS. This analysis indicated that HPS was converted into compound V with a retention time of 2.6 min (Fig. 3B). Negative ESI-MS analysis of compound V showed a major fragment at *m/z* 197 (Fig. 3C). Based on a comparison of the retention time and *m/z* value of the deprotonated ion with those of the authentic sample, compound V was identified as syringic acid (MW, 198; see Fig. S1I and J in the supplemental material). In order to clarify the more detailed catabolic pathway of HPS, cell extracts (>10 kDa) prepared from SYK-6 cells grown in Wx-SEMP were incubated with 200  $\mu$ M HPS for 16 h. An accumulation of compound VI with a retention time of 1.8 min was observed (Fig. 3E). Negative ESI-MS analysis of compound VI showed a major fragment at *m/z* 326 (Fig. 3F), suggesting the formation of an imine derivative of 3-(4-hydroxy-3,5-dimethoxyphenyl)-3-oxopropanal (SAL), 2-((3-hydroxy-3-(4-hydroxy-3,5-dimethoxyphenyl)allylidene)amino)-2-(hydroxymethyl)propane-1,3-diol, or its oxazolidine product (SAL-Tris; MW, 327).

In the presence of 500  $\mu$ M NAD<sup>+</sup>, the same cell extract (>10 kDa) converted HPS into SAL-Tris (compound VI) and compound VII with a retention time of 3.3 min (Fig. 3H). Negative ESI-MS analysis of compound VII showed fragments at *m/z* 239 and 195, which seemed to represent the deprotonated ion and its decarboxylated ion, respectively (Fig. 3I). From these results, compound VII was identified as 3-(4-hydroxy-3,5-dimethoxyphenyl)-3-oxopropanoic acid (designated SAA; MW, 240). These results



**FIG 3** HPLC-MS analysis of HPS metabolites. SYK-6 resting cells ( $OD_{600}$  of 5.0) and SYK-6 cell extracts ( $>10$  kDa;  $500 \mu\text{g}$  of protein/ml) were incubated with 1 mM HPS (A and B) and  $200 \mu\text{M}$  HPS (D and E), respectively. The same cell extract ( $>10$  kDa) was incubated with HPS in the presence of  $500 \mu\text{M}$   $\text{NAD}^+$  (G and H). Portions of the reaction mixtures were collected at the start (A, D, and G) and after 4 h (B) and 16 h (E and H) of incubation and then analyzed by HPLC. The negative-ion ESI-MS spectra of compounds V, VI, and VII are shown in panels C, F, and I, respectively.

indicate that HPS was oxidized to SAA via SAL and may be degraded by the same enzyme system involved in HPV catabolism (Fig. 1).

**Basic properties of the enzyme involved in the conversion of HPV.** In order to characterize the enzymes involved in the catabolism of HPV in SYK-6, cofactor requirements and induction profiles of the HPV-transforming activities in SYK-6 were examined. The effects of the addition of 1-methoxy-5-methylphenazinium methylsulfate (PMS), flavin adenine dinucleotide (FAD) + PMS, and  $\text{NAD}^+$  on the enzyme activities in converting  $200 \mu\text{M}$  HPV were investigated. When an extract of SYK-6 cells grown in Wx-SEMP was incubated with HPV in the presence of PMS, the extract showed 1.8-fold-higher activity ( $4.2 \pm 0.7 \text{ nmol} \cdot \text{min}^{-1} \cdot \text{mg}^{-1}$ ) than that in the absence of cofactors ( $2.4 \pm 0.8 \text{ nmol} \cdot \text{min}^{-1} \cdot \text{mg}^{-1}$ ). On the other hand, the addition of FAD or  $\text{NAD}^+$  had no effect on the activity. These results suggested that an oxidase(s) that requires an electron acceptor is involved in HPV oxidation. The HPV-oxidizing activity of an extract of SYK-6 cells grown with GGE was also measured in the presence of PMS. However, no activation was observed, suggesting the constitutive expression of the gene(s) responsible for the oxidation of HPV.


**Isolation of the gene involved in the conversion of HPV.** A cosmid library of SYK-6 constructed in *Sphingomonas sanguinis* IAM 12578 was screened for clones

capable of degrading HPV. Of the 1,000 clones tested, three transconjugants degraded HPV, and cosmids pSA53, pSA88, and pSA684 were isolated. Southern hybridization analysis of the cosmid clones using Sall-digested pSA53 as a probe suggested that a 3.6-kb Sall fragment, a 2.0-kb Sall fragment, and two 1.0-kb Sall fragments were commonly present in the above cosmids. Subcloning and nucleotide sequencing showed that these Sall fragments were present in a 17.9-kb DNA fragment that contained 13 genes corresponding to SLG\_12790 through to SLG\_12910. In this fragment, SLG\_12830 revealed 36 to 39% amino acid sequence identity with the glucose-methanol-choline (GMC) oxidoreductase family enzymes, including (i) 3-(2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-7-methoxy-2,3-dihydrobenzofuran-5-yl)acrylic acid (DCA-C) oxidases (PhcC and PhcD) involved in the catabolism of dehydrodiconiferyl alcohol (DCA) in SYK-6 (40), (ii) AlkJ, which is involved in the oxidation of primary alcohols to aldehydes in *Pseudomonas putida* GPO1 (41), and (iii) polyethylene glycol dehydrogenase (PegA) of *Sphingopyxis terrae* (42).

**The gene product of SLG\_12830 catalyzes oxidation of HPV.** SLG\_12830 fused with a His tag at the 5' terminus was coexpressed in *Escherichia coli* with the trigger factor chaperone. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of a cell extract prepared from *E. coli* harboring pCold12830 and pTf16 (*hpvZ*-expressing *E. coli*) showed the expression of SLG\_12830 (see Fig. S2 in the supplemental material). In order to determine the reaction product, resting cells of the *E. coli* transformant were incubated with 200  $\mu$ M HPV in Tris-HCl buffer. HPLC-MS analysis showed that HPV was almost completely converted and that VAL-Tris and compound VIII with a retention time of 5.4 min were produced (Fig. 4A). When the same incubation was performed in water, a significant amount of compound VIII was observed without the generation of VAL-Tris (Fig. 4B). Positive ESI-MS analysis of compound VIII showed a major fragment at  $m/z$  195 (Fig. 4C), suggesting that compound VIII was VAL (MW, 194). These results indicated that the gene product of SLG\_12830 has the ability to oxidize HPV into VAL.

**Role of SLG\_12830 in HPV and HPS catabolism.** In order to examine whether SLG\_12830 is indeed involved in the conversion of HPV in SYK-6, an SLG\_12830 mutant (SME059) was created (see Fig. S3A and B in the supplemental material). The ability of SME059 to convert HPV was assessed using resting cells. SME059 was no longer able to convert HPV, whereas the wild type completely converted 200  $\mu$ M HPV within 3 h (Fig. 4D). When GGE was used as a substrate, the conversion rates of the wild-type and SME059 strains were almost identical (Fig. 4E). However, only SME059 accumulated HPV at a concentration approximately equimolar to the added GGE (Fig. 4E). In addition, SME059 also completely lost the ability to convert HPS (Fig. 4F). The HPV conversion defect of SME059 was complemented by the introduction of pJB12830 carrying SLG\_12830 (Fig. 4G). These results demonstrated that GGE is catabolized through HPV in SYK-6 and that SLG\_12830 is essential for the catabolism of HPV and HPS; thus, we designated this gene *hpvZ*.

**Cellular localization of HpvZ.** In order to determine the cellular localization of HpvZ, HPV-transforming activities of soluble and membrane fractions of SYK-6 cells were compared. The HPV transforming activity in the cytoplasmic and membrane fractions were estimated to be  $0.6 \pm 0.1$  nmol  $\cdot$  min<sup>-1</sup> (7.5 mg of protein) and  $0.5 \pm 0.1$  nmol  $\cdot$  min<sup>-1</sup> (0.9 mg of protein), respectively, based on the results that the ratio of the amount of proteins in the soluble and membrane fractions was 75:9.4 (40). These results indicated that HpvZ is localized to cytoplasm and cytoplasmic membrane. Similarly, the GMC oxidoreductase family proteins, PhcC and PhcD from SYK-6, and PegA from *S. terrae* have been suggested to localize to both the soluble and membrane fractions (40, 43). Another GMC oxidoreductase family protein, AlkJ from *P. putida* GPO1, and glucose dehydrogenase from *Pseudomonas fluorescens*, were localized to the membrane (41, 44). Since there are no predicted signal sequences or hydrophobic transmembrane segments in the deduced amino acid sequence of HpvZ, this enzyme



**FIG 4** Function and role of *hpvZ* in SYK-6. (A and B) Conversion of 200  $\mu\text{M}$  HPV by resting cells of *E. coli* harboring pCold12830 and pTf16 in Tris-HCl buffer (pH 7.5) (A) and water (B). Portions of the reaction mixtures were collected after 6 h of incubation and analyzed by HPLC. The ESI-MS spectra of compound VIII (positive mode) are shown in panel C. (D to F) Conversions of 200  $\mu\text{M}$  HPV (D), GGE (E), and HPS (F) by resting cells of SYK-6 (open symbols) and SME059 (closed symbols). Circles, triangles, and diamonds indicate the concentrations of HPV, GGE, and HPS, respectively. (G) Complementation of SME059 with pJB12830. Cells of SYK-6 harboring pJB864 (circles), SME059 harboring pJB864 (triangles), and SME059 harboring pJB12830 (diamonds) were incubated with 200  $\mu\text{M}$  HPV. Experiments shown in panels D to G were performed in triplicate, and the data represent averages  $\pm$  the standard deviations.

appears to be a peripheral cytoplasmic membrane protein like other membrane-associated GMC oxidoreductase family enzymes.

**Enzyme properties of HpvZ.** Cell extracts prepared from *hpvZ*-expressing *E. coli* were fractionated into the soluble and membrane fractions. SDS-PAGE of both fractions showed the expression of *hpvZ* (see Fig. S2 in the supplemental material). The specific activity for HPV of the membrane fraction was estimated to be  $26 \pm 6 \text{ nmol} \cdot \text{min}^{-1} \cdot \text{mg}^{-1}$ . However, the soluble fraction showed no activity even in the presence of PMS. The membrane fraction was treated with each of 10 different detergents, and the solubilized HpvZ was obtained from the membrane fractions treated with *n*-dodecylphosphocholine and 5-cyclohexyl-1-pentyl- $\beta$ -D-maltoside. However, purified HpvZ was not obtained due to the lack of adsorption of the enzyme to a nickel affinity column. Therefore, the enzyme properties of HpvZ were examined using the membrane fraction prepared from extracts of *hpvZ*-expressing *E. coli* cells.

The optimum pH and temperature for the activity of HpvZ were determined to be pH 8.5 to 9.0 and at 40 to 45°C, respectively (see Fig. S4 in the supplemental material).

The substrate range of HpvZ was examined using 200  $\mu\text{M}$  HPV, HPS, coniferyl alcohol, sinapyl alcohol, cinnamyl alcohol, 3-(4-hydroxyphenyl)-1-propanol, homovanil-



**TABLE 1** Substrate range of HpvZ

Compound	Avg sp act <sup>a</sup> (nmol · min <sup>-1</sup> · mg <sup>-1</sup> ) ± SD
HPV	26 ± 6
HPS	40 ± 5
Coniferyl alcohol	8.0 ± 0.4
Sinapyl alcohol	52 ± 7
Cinnamyl alcohol	40 ± 9
3-(4-Hydroxyphenyl)-1-propanol	8 ± 2
Homovanillyl alcohol	ND
Vanillyl alcohol	ND
GGE	ND
MPHPV	ND
DCA	13 ± 2
DCA-C	ND

<sup>a</sup>The membrane fraction of *hpvZ*-expressing *E. coli* (300  $\mu$ g of protein/ml) was incubated with 200  $\mu$ M substrate in the presence of 500  $\mu$ M PMS. The data represent the averages  $\pm$  standard deviations of three independent experiments. ND, not detected.

lyl alcohol, vanillyl alcohol, GGE, MPHPV, DCA, and DCA-C (see Fig. S5 in the supplemental material). HPLC analyses of the reaction mixtures indicated that HpvZ showed no activity for a C<sub>6</sub>-C<sub>2</sub> monomeric alcohol (homovanillyl alcohol), a C<sub>6</sub>-C<sub>1</sub> monomeric alcohol (vanillyl alcohol), and lignin-derived biaryls, including GGE, MPHPV, and DCA-C (Table 1). On the other hand, HpvZ showed activities toward all of the C<sub>6</sub>-C<sub>3</sub> monomeric alcohols (3-phenyl-1-propanol derivatives; Table 1). Generally, GMC oxidoreductase family enzymes act on hydroxyl groups of alcohols, carbohydrates, or sterols (45). For example, an aryl-alcohol oxidase from *Pleurotus eryngii* is able to oxidize a variety of aromatic alcohols and aldehydes, including coniferyl alcohol and cinnamyl alcohol (46). On the contrary, PhcC and PhcD specifically oxidize the alcohol group at C<sub>γ</sub> of the A-ring side chain of DCA-C and DCA, although PhcC has a weak activity for coniferyl alcohol (40). HpvZ was able to oxidize the alcohol group at C<sub>γ</sub> of the B-ring side chain of DCA, which is different from the regioselectivity of PhcC and PhcD (data not shown).

Among the enzymes belonging to the GMC oxidoreductase family, an FAD-binding domain (GMC\_oxred\_N; Pfam PF00732) is conserved in the N-terminal region. This domain includes the typical GxGxxG/A sequence motif, which is indicative of the Rossmann fold involved in binding the ADP moiety of FAD (47). A substrate-binding domain is also conserved in the C-terminal region, although this domain is less conserved. In addition, an active-site histidine, which can assist in substrate oxidation and FAD reoxidation by molecular oxygen, is generally conserved (45, 47). These domains and the residue are also conserved in HpvZ (see Fig. S6 in the supplemental material). To identify the flavin cofactor in HpvZ, a supernatant obtained by heat treating the membrane fraction containing HpvZ was analyzed by HPLC. However, a significant peak was not observed. Furthermore, the specific activities in the presence of FAD (26  $\pm$  8 nmol · min<sup>-1</sup> · mg<sup>-1</sup>) or flavin mononucleotide (27  $\pm$  1 nmol · min<sup>-1</sup> · mg<sup>-1</sup>) were almost equivalent to that in the absence of any flavin cofactors (26  $\pm$  6 nmol · min<sup>-1</sup> · mg<sup>-1</sup>). GMC oxidoreductase family enzymes generally contain either covalently or noncovalently bound FAD (45). Choline oxidase from *Arthrobacter globiformis* (48) and pyranose dehydrogenase (*Am*PDH) from *Agaricus meleagris* (49) have covalently bound FAD. Our results suggested that HpvZ may also covalently bind to FAD. Moreover, although purified inactive HpvZ was obtained from the soluble fraction of the *hpvZ*-expressing *E. coli* cells, UV-visible spectra of the enzyme showed no absorption at 454 nm, indicating the absence of flavin cofactor in the enzyme (data not shown). This result suggested that HpvZ produced in the *E. coli* cytoplasm lacked FAD as a prosthetic group.


**In vivo electron acceptor of HpvZ.** AlkJ and PegA are able to use ubiquinone (CoQ<sub>10</sub>) and its derivatives (CoQ<sub>0</sub> and CoQ<sub>1</sub>) as electron acceptors for the oxidation of their substrates (41, 42). PhcC and PhcD have also been shown to be able to use CoQ<sub>0</sub> and CoQ<sub>1</sub> as electron acceptors, as well as PMS (40). Furthermore, electron transport

from AlkJ to cytochrome *c* in the presence of CoQ<sub>1</sub> has been observed (41). Therefore, the electrons that are removed from the substrate by AlkJ, PegA, and PhcC/PhcD are thought to be transferred to the respiratory chain. Based on these observations, we predicted that HpvZ could use ubiquinone as an electron acceptor in the oxidation of HPV. When using a membrane fraction of SYK-6 cells harboring pJB12830 (*hvpZ*-expressing SYK-6), HpvZ showed 1.2- and 1.6-fold-higher specific activities in the presence of CoQ<sub>0</sub> ( $27 \pm 2 \text{ nmol} \cdot \text{min}^{-1} \cdot \text{mg}^{-1}$ ) and CoQ<sub>1</sub> ( $36 \pm 6 \text{ nmol} \cdot \text{min}^{-1} \cdot \text{mg}^{-1}$ ), respectively, than that in the absence of cofactors ( $22 \pm 1 \text{ nmol} \cdot \text{min}^{-1} \cdot \text{mg}^{-1}$ ). The specific activity in the presence of CoQ<sub>1</sub> was almost equivalent to that obtained using PMS ( $40 \pm 3 \text{ nmol} \cdot \text{min}^{-1} \cdot \text{mg}^{-1}$ ). These results suggested that HpvZ is able to use ubiquinone as an electron acceptor *in vivo*. However, no increase in HpvZ activity was observed when the membrane fraction of *hvpZ*-expressing *E. coli* was used. The difference in the increase in HpvZ activities between the membrane fractions of *hvpZ*-expressing SYK-6 and *E. coli* cells in the presence of ubiquinone derivatives may be caused by a difference in the abundance of ubiquinone in the membrane fractions.

**Identification of the ALDH genes responsible for the conversion of VAL.** To obtain more information on the properties of the enzymes involved in the conversion of VAL in SYK-6, cofactor requirements of the enzyme activity were examined. Cell extracts (>10 kDa) of SYK-6 grown in lysogeny broth (LB) were incubated with 200  $\mu\text{M}$  HPV in the presence of FAD, NAD<sup>+</sup>, and NADP<sup>+</sup> for 2 h. In the presence of NAD<sup>+</sup> and NADP<sup>+</sup>, VAA accumulated to levels of  $95 \pm 9 \mu\text{M}$  and  $86 \pm 6 \mu\text{M}$ , respectively, while the accumulation of VAA was not observed in the presence of FAD. These results suggested that NAD<sup>+</sup>/NADP<sup>+</sup>-dependent ALDHs play a major role in VAL oxidation.

Previously, 23 ALDH genes were predicted to be present in the SYK-6 genome (50, 51). To examine the ability of the putative 23 ALDH gene products to oxidize VAL, these genes were expressed in *E. coli* using expression plasmids constructed in a previous study (51). SDS-PAGE showed sufficient gene expression, except for SLG\_32240 and SLG\_34940 (see Fig. S7 in the supplemental material). Since HPV was converted to VAL-Tris during incubation with HpvZ in Tris-HCl buffer, we used HEPES buffer (pH 7.5) and sodium phosphate buffer (pH 7.5) to prepare VAL from HPV using HpvZ. However, HPV was converted to unknown products in HEPES buffer, and the reaction product was not detected in sodium phosphate buffer (data not shown). In addition, the HPV conversion rate was significantly decreased in HEPES buffer (approximately 60%) and sodium phosphate buffer (approximately 50%). Therefore, we examined the ability of these 21 ALDHs to convert VAL by measuring the amount of VAA produced from HPV when HPV was reacted with both HpvZ and each ALDH in Tris-HCl buffer (pH 7.5). Resting cells of *E. coli* expressing each ALDH gene and *hvpZ*-expressing *E. coli* were mixed and incubated with 100  $\mu\text{M}$  HPV for 12 h. When resting cells of *E. coli* harboring a vector and the *hvpZ*-expressing *E. coli* were incubated with HPV, VAA was not generated, whereas VAL-Tris accumulated. On the other hand, when *E. coli* cells carrying each of the 13 ALDH genes (SLG\_07270, SLG\_07610, SLG\_07790, SLG\_09510, SLG\_11410, SLG\_12800, SLG\_18210, SLG\_20400, SLG\_27910 [*bzaA*], SLG\_27920 [*bzaB*], SLG\_28150, SLG\_31150, and SLG\_38120) were used instead of the control vector, HPV was converted into VAA (Fig. 5A). Of the 13 ALDH genes, when incubating with *E. coli* carrying SLG\_07270, SLG\_12800, SLG\_18210, SLG\_20400, *bzaA*, *bzaB*, and SLG\_31150, larger amounts of VAA accumulated (Fig. 5A). We therefore measured the VAA production time course using *E. coli* carrying these seven ALDH genes and the *hvpZ*-expressing *E. coli*. Of these, *E. coli* carrying SLG\_07270, SLG\_12800, SLG\_20400, and *bzaB* produced a greater amount of VAA than *E. coli* carrying one of the three other ALDH genes (Fig. 5B). Specifically, when using *E. coli* carrying SLG\_20400, the amount of VAA produced was the greatest, and no VAL-Tris was detected at any of the sampling points (Fig. 5B).


In order to examine whether SLG\_07270, SLG\_12800, SLG\_20400, and *bzaB* are involved in the conversion of VAL in SYK-6, SLG\_07270 mutant (SME092) and SLG\_20400 mutant (SME061) were created (see Fig. S3C to F in the supplemental



**FIG 5** Identification of ALDH genes involved in VAL conversion. (A) Resting cells of *E. coli* carrying each of the 23 SYK-6 ALDH genes ( $OD_{600}$  of 1.0) were incubated with 100  $\mu$ M HPV in the presence of resting cells of *E. coli* harboring pCold12830 and pTf16 ( $OD_{600}$  of 5.0). The amounts of VAA produced in the reaction mixtures containing each of the ALDH gene-expressing cells are shown as the relative ratio to that in the reaction mixture containing SLG\_20400-expressing cells. ND, VAA was not detected. (B) Time course of the production of VAA during incubation of 100  $\mu$ M HPV with cells of *E. coli* harboring pCold12830 and pTf16 ( $OD_{600}$  of 10.0) and *E. coli* carrying the following ALDH genes ( $OD_{600}$  of 1.0): SLG\_20400 (●), SLG\_07270 (▲), *bzaB* (■), SLG\_12800 (◆), SLG\_18210 (○), *bzaA* (△), and SLG\_31150 (□). *E. coli* cells harboring pET-21a(+) were used as a negative control (◇). (C) Accumulation of VAL-Tris during incubation of 1 mM HPV with cells of *E. coli* harboring pCold12830 and pTf16 ( $OD_{600}$  of 10.0) and the following mutants of the ALDH genes ( $OD_{600}$  of 0.5): SME061 ( $\Delta$ SLG\_20400; ●), SME045 ( $\Delta$ *bzaB*; ■), SME092 ( $\Delta$ SLG\_07270; ▲), and SME031 ( $\Delta$ SLG\_12800; ◆). SYK-6 cells were used as a control (◇). These experiments were performed in triplicate, and the data represent averages  $\pm$  the standard deviations.

material). Resting cells of SME092, SME061, and the previously created SLG\_12800 mutant (SME031) and *bzaB* mutant (SME045) were incubated with 1 mM HPV in the presence of *hvpZ*-expressing *E. coli* cells. SME061 accumulated a 1.8-fold greater amount of VAL-Tris than the wild type or the other mutants after 20 h of incubation (Fig. 5C). These results suggested that SLG\_20400 is involved in VAL oxidation. However, SME061 accumulated only 75  $\mu$ M VAL-Tris at 20 h of incubation. Therefore, multiple ALDHs, including SLG\_20400, appear to be involved in the conversion of VAL. Our previous phylogenetic analysis of the 23 ALDH genes in SYK-6 and other known ALDH genes indicated that 13 SYK-6 ALDH genes, the products of which showed VAL oxidation activities, are phylogenetically diverse (51). SLG\_20400 clustered with *calB*, which encodes coniferyl aldehyde dehydrogenase from *Pseudomonas* sp. strain HR199, which shared 33% amino acid sequence identity with SLG\_20400 (51, 52). The involvement of multiple ALDH genes in SYK-6 was also shown in the oxidation of vanillin, syringaldehyde, and an intermediate metabolite of DCA (DCA-L) (50, 51). Another example of the involvement of multiple ALDH genes in the conversion of vanillin has also been reported for *P. putida* KT2440 (53). Since ALDHs exhibit broad substrate ranges in general, multiple ALDHs are likely to play roles in the oxidation of aromatic aldehydes to their acids.

**Candidate genes for the catabolism of VAA.** In a previous report, Palamuru et al. detected vanillin as a metabolite when SYK-6 cells were incubated with GGE (24). However, vanillin was not observed during the conversion of HPV (Fig. 2). In order to examine whether vanillin is an actual intermediate in HPV catabolism, resting cells of a



**FIG 6** Conversion of VAA by a *desV ligV* double mutant. Resting cells of the *desV ligV* double mutant (SME077) were incubated with 100  $\mu$ M VAA (A to C) and 1 mM ferulate (D to F). Portions of the reaction mixtures were collected at the start (A and D) and after 2 h (B and E) and 4 h (C and F) of incubation and then analyzed by HPLC using the two different analytical conditions described in Materials and Methods. The retention times of vanillin separated under the analytical conditions for the reaction mixtures of VAA (A to C) and ferulate (D to F) were 2.9 and 2.4 min, respectively.

*desV ligV* double mutant (SME077), which has a weak ability to convert vanillin (51), were incubated with 100  $\mu$ M VAA or 1 mM ferulate. Only the accumulation of vanillate and acetovanillone was observed at any of the sampling points (1, 2, 4, 6, and 24 h) in the mixture for the VAA conversion, whereas the mixture for the ferulate conversion accumulated a significant amount of vanillin in addition to vanillate (Fig. 6; chromatograms at 2 and 4 h of incubation are shown). In addition, when a cell extract ( $>10$  kDa) of SME077 was incubated with 100  $\mu$ M VAA in the presence of CoA,  $MgSO_4$ , and ATP, only the accumulation of vanillate and acetovanillone was observed (see Fig. S8 in the supplemental material). These results suggested that VAA was catabolized to vanillate without passing through vanillin as an intermediate.

We hypothesized that the feruloyl-CoA synthetase gene (*ferA*) and feruloyl-CoA hydratase/lyase genes (*ferB* and *ferB2*) may be involved in VAA catabolism based on the structural similarity between VAA and ferulic acid (36). These genes were adequately expressed in *E. coli* (see Fig. S9 in the supplemental material). When crude FerA was incubated with 100  $\mu$ M VAA in the presence of CoA,  $MgSO_4$ , and ATP for 60 min, compound IX with a retention time of 1.7 min was generated (see Fig. S10B in the supplemental material). Negative ESI-MS analysis of compound IX showed fragments at  $m/z$  959 ( $[M - H]^-$ ) and 479 ( $[M - 2H]^{2-}$ ), suggesting that compound IX was the CoA derivative of VAA (VAA-CoA; MW, 960) (see Fig. S10E in the supplemental material). However, no other peak except VAA-CoA was observed when crude enzymes of FerA + FerB and FerA + FerB2 were incubated with VAA, respectively (see Fig. S10C and D in the supplemental material). Therefore, FerB and FerB2 appear to be not involved in the conversion of VAA-CoA.

In order to examine whether *ferA* is indeed involved in the conversion of VAA in SYK-6, resting cells of a previously created *ferA* mutant (SME009) grown in LB were incubated with 100  $\mu$ M VAA. SME009 showed a higher conversion rate for VAA than that of the wild type (see Fig. S11 in the supplemental material), suggesting that *ferA* is not essential for the catabolism of VAA. The reason for the high conversion rate of VAA of SME009 is not clear but disruption of *ferA* may cancel the substrate competition between FerA and (an) unidentified true VAA-converting enzyme(s).

Recently, the catabolic pathway of *p*-hydroxycinnamate derivatives, such as dihydroferulate, ferulate, and *p*-coumarate in *Rhodococcus jostii* RHA1, were characterized (37). In this pathway, dihydroferulate was catabolized to vanillate via VAA-CoA. VAA-CoA was converted into vanillate and acetyl-CoA by the gene product of *couO* (ro0512), which encodes 4-hydroxyphenoxy- $\beta$ -ketoacyl-CoA hydrolase. CouO was predicted to be a zinc-dependent metalloenzyme belonging to amidohydrolase superfamily. Orthologs of *couO*, showing 53 to 58% amino acid sequence identity, have also been found and characterized in *Agrobacterium fabrum* C58 (Atu1421) (38) and *Corynebacterium glutamicum* (*phdC*) (39). In the SYK-6 genome, we found SLG\_12680, which exhibited 50% amino acid sequence identity with CouO. We are currently investigating the function of the gene product of SLG\_12680 and exploring the actual VAA-converting enzyme gene.

**Genome search for orthologs of *hvpZ* in other bacteria.** Since HpvZ is essential for the catabolism of HPV and HPS, the presence of this gene determines whether bacteria can utilize the A-ring portion of  $\beta$ -aryl ether compounds. BLAST searches of *hvpZ* were carried out to determine the distribution of its orthologs among bacteria. The *hvpZ* orthologs that showed high amino acid sequence identity (62%–92%) were found in *Altererythrobacter* sp. strain Root672 (ASD76\_15935), *Altererythrobacter atlanticus* (WYH\_02786), *Erythrobacter* sp. strain SG61-1L (SZ64\_15220), *Sphingomonas hengshuiensis* WHSC-8 (TS85\_07880), and *Sphingobium* sp. strain 66-54 (BGP16\_16810). All of these bacteria possess orthologs of the genes responsible for the conversion of GGE into HPV. Among these strains, SG61-1L was reported to be able to utilize GGE as the sole source of carbon and energy (24). In contrast, *Novosphingobium* sp. strain MBES04 accumulated HPV from GGE (23). Consistent with this observation, MBES04 possesses GMC oxidoreductase family enzyme genes, whose products showed less than 37% amino acid sequence identity with HpvZ. Similarly, no *hvpZ* orthologs were found in *Novosphingobium* sp. strain PP1Y and *Novosphingobium aromaticivorans* DSM 12444, which possess orthologs of the genes responsible for converting GGE into HPV. Due to the lack of *hvpZ*, PP1Y and DSM 12444 also appear to be able to utilize only the portion of the B-ring of  $\beta$ -aryl ether compounds as carbon and energy sources.

## MATERIALS AND METHODS

**Bacterial strains, plasmids, and culture conditions.** The strains and plasmids used in this study are listed in Table 2. *Sphingobium* sp. strain SYK-6 and its mutants were grown in LB, Wx-SEMP, and Wx-SEMP containing 5 mM GGE at 30°C. *S. sanguinis* IAM 12578 was grown in LB at 30°C. When necessary, 50 mg kanamycin/liter, 100 mg streptomycin/liter, or 300 mg carbenicillin/liter were added to the cultures. *E. coli* strains were grown in LB at 37°C. For cultures of cells carrying antibiotic resistance markers, the media for *E. coli* transformants were supplemented with 100 mg ampicillin/liter, 25 mg kanamycin/liter, or 12.5 mg chloramphenicol/liter. The synthesis of each HPS and HPV compound is described in detail below (Fig. 7).

**Synthesis of HPS (S-Hibbert-Westwood-Lancefield ketone).** (i) **Synthesis of 4-((tert-butyl-dimethylsilyl)oxy)-3,5-dimethoxybenzaldehyde (compound A).** To synthesize compound A, 4-dimethylaminopyridine (4-DMAP; 13.4 g, 109.8 mmol, 1.0 eq) and imidazole (Imid; 14.9 g, 219.6, 2.0 eq) were added to a stirring solution of syringaldehyde (20.0 g, 109.8 mmol, 1.0 eq) in dichloromethane (DCM; 600 ml,  $c = 0.18$  M). The resulting mixture was allowed to stir for 5 min, and then *tert*-butyldimethylchlorosilane (TBSCl; 17.3 g, 115.3 mmol, 1.1 eq) was added. The mixture was stirred at room temperature for 1 h. After the reaction had reached completion, it was neutralized with a saturated aqueous solution of  $\text{NH}_4\text{Cl}$  ( $2 \times 300$  ml). The organic layer was further washed with water (500 ml) and brine (300 ml), dried with  $\text{MgSO}_4$ , filtered, and concentrated *in vacuo*. Purification by silica gel chromatography using 5 to 10% ethyl acetate in petroleum ether afforded compound A as a white solid (26.6 g, 89.8 mmol, 82%). Analytical data for compound A agreed with those reported previously (54).  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  9.79 (s, 1H), 7.07 (s, 2H), 3.84 (s, 6H), 0.98 (s, 9H), 0.13 (s, 6H);  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ )  $\delta$  191.1, 152.0, 140.7, 129.4, 106.7, 55.8, 25.8, 18.9,  $-4.46$ .

(ii) **Synthesis of ethyl 3-(4-((tert-butyl)dimethylsilyl)oxy)-3,5-dimethoxyphenyl)-3-hydroxypropanoate (compound B).** Ethyl acetate (4.2 g, 47.5 mmol, 1.3 eq) was added to a cooled solution of lithium bis(trimethylsilyl)amide (LiHMDS; 1.0 M in tetrahydrofuran [THF]; 47.5 ml, 47.5 mmol, 1.3 eq) in THF (100 ml) at  $-78^\circ\text{C}$ . After 15 min, a solution of compound A (10.8 g, 36.6 mmol, 1.0 eq) in THF (20 ml, overall  $c = 0.30$  M) was added at  $-78^\circ\text{C}$ , and the resulting mixture was left to stir at this temperature for 1 h. After the reaction had reached completion, it was quenched with saturated aqueous solution of  $\text{NH}_4\text{Cl}$  ( $2 \times 300$  ml) and extracted with ethyl acetate (500 ml). The organic layer was further washed with water (500 ml) and brine (300 ml), dried with  $\text{MgSO}_4$ , filtered, and concentrated *in vacuo*. Purification by silica gel chromatography using 10 to 20% ethyl acetate in petroleum ether afforded compound B as a

**TABLE 2** Strains and plasmids used in this study

Strain or plasmid	Relevant characteristic(s) <sup>a</sup>	Reference or source
<b>Strains</b>		
<i>Sphingobium</i> sp.		
SYK-6	Wild type; Nal <sup>r</sup> Sm <sup>r</sup>	65
SME009	SYK-6 derivative; <i>ferA::kan</i> ; Nal <sup>r</sup> Sm <sup>r</sup> Km <sup>r</sup>	36
SME031	SYK-6 derivative; SLG_12800:: <i>kan</i> ; Nal <sup>r</sup> Sm <sup>r</sup> Km <sup>r</sup>	66
SME045	SYK-6 derivative; <i>bzaB::tet</i> ; Nal <sup>r</sup> Sm <sup>r</sup> Tc <sup>r</sup>	67
SME059	SYK-6 derivative; <i>hvpZ::kan</i> ; Nal <sup>r</sup> Sm <sup>r</sup> Km <sup>r</sup>	This study
SME061	SYK-6 derivative; ΔSLG_20400; Nal <sup>r</sup> Sm <sup>r</sup>	This study
SME077	SYK-6 derivative; <i>desV::cat ligV::kan</i> ; Nal <sup>r</sup> Sm <sup>r</sup> Cm <sup>r</sup> Km <sup>r</sup>	51
SME092	SYK-6 derivative; SLG_07270:: <i>kan</i> ; Nal <sup>r</sup> Sm <sup>r</sup> Km <sup>r</sup>	This study
<i>Sphingomonas sanguinis</i> IAM 12578	Nal <sup>r</sup>	68
<i>Escherichia coli</i>		
BL21(DE3)	F <sup>-</sup> <i>ompT hsdS<sub>B</sub>(r<sub>B</sub><sup>-</sup> m<sub>B</sub><sup>-</sup>) gal dcm</i> (DE3); T7 RNA polymerase gene under the control of the <i>lacUV5</i> promoter	69
HB101	<i>recA13 supE44 hsd20 ara-14 proA2 lacY1 galK2 rpsL20 xyl-5 mtl-1</i>	70
NEB 10-beta	<i>araD 139 Δ(ara-leu)7697 fhuA lacX74 galK (φ80 ΔlacZ ΔM15) recA1 endA1 nupG rpsL (Sm<sup>r</sup>) Δ(mrr-hsdRMS-mcrBC)</i>	New England Biolabs
<b>Plasmids</b>		
pVK100	Broad-host-range cosmid vector; Km <sup>r</sup> Tc <sup>r</sup>	62
pRK2013	Tra <sup>+</sup> Mob <sup>+</sup> ColE1 replicon; Km <sup>r</sup>	71
pT7Blue	Cloning vector; Ap <sup>r</sup>	Novagen
pBluescript II KS(+) and SK(+)	Cloning vector; Ap <sup>r</sup>	72
pUC19	Cloning vector; Ap <sup>r</sup>	73
pET-16b	Expression vector; T7 promoter; Ap <sup>r</sup>	Novagen
pET-21a(+)	Expression vector; T7 promoter; Ap <sup>r</sup>	Novagen
pCold I	Expression vector; <i>cspA</i> promoter; Ap <sup>r</sup>	TaKaRa Bio
pTf16	Expression vector for <i>tig</i> ; <i>araB</i> promoter; Cm <sup>r</sup>	TaKaRa Bio
pK18 <i>mobsacB</i>	<i>oriT sacB</i> ; Km <sup>r</sup>	74
pK19 <i>mobsacB</i>	<i>oriT sacB</i> ; Km <sup>r</sup>	74
pIK03	KS(+) with a 1.3-kb EcoRV fragment carrying <i>kan</i> of pUC4K; Ap <sup>r</sup> Km <sup>r</sup>	75
pJB864	RK2 broad-host-range expression vector; Ap <sup>r</sup> Cb <sup>r</sup> P <sub>m</sub> <i>xylS</i>	76
pAK405	Plasmid for allelic exchange and markerless gene deletions in sphingomonads; Km <sup>r</sup>	64
pSA53	pVK100 with partially Sall-digested fragments of SYK-6 carrying <i>hvpZ</i>	This study
pSA88	pVK100 with partially Sall-digested fragments of SYK-6 carrying <i>hvpZ</i>	This study
pSA684	pVK100 with partially Sall-digested fragments of SYK-6 carrying <i>hvpZ</i>	This study
pT7B12830	pT7Blue with a 1.7-kb PCR amplified fragment carrying <i>hvpZ</i>	This study
pCold12830	pCold I with a 1.7-kb NdeI-BamHI fragment carrying <i>hvpZ</i> from pT7B12830	This study
pBH37F	SK(+) with a 3.7-kb HindIII fragment carrying <i>hvpZ</i> from pSA53	This study
pUC12830	pUC19 with a 2.0-kb Sall fragment of pBH37F	This study
pUC12830K	pUC12830 with a 1.3-kb Sall-BamHI fragment of pIK03 carrying <i>kan</i>	This study
pKmb12830K	pK19 <i>mobsacB</i> with a 3.1-kb Sall fragment of pUC12830K	This study
pJB12830	pJB864 with a 2.3-kb BamHI-SacII (blunted) fragment carrying <i>hvpZ</i> from pBH37F	This study
pLVH	pET-21a(+) with a 1.9-kb NdeI-XhoI fragment carrying <i>ligV</i>	77
pT21-0727	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_07270	51
pT21-0761	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_07610	51
pT21-0779	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_07790	51
pT21-0940	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_09400	51
pT21-0951	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_09510	51
pT21-0992	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_09920	51
pT21-1141	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_11410	51
pT21-1202	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_12020	51
pT21-1219	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_12190	51
pT21-1280	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_12800	51
pT21-1821	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_18210	51
pT21-2040	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_20400	51
pT21-2721	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_27210	51
pT21-2791	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying <i>bzaA</i>	51
pT21-2792	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying <i>bzaB</i>	51
pT21-2815	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_28150	51
pT21-2832	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_28320	51
pT21-3115	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_31150	51

(Continued on next page)

TABLE 2 (Continued)

Strain or plasmid	Relevant characteristic(s) <sup>a</sup>	Reference or source
pT21-3224	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_32240	51
pT21-3494	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_34940	51
pT21-3812	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_38120	51
pT21-p0068	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_p_00680	51
pKS0727	KS(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_07270	51
pKmb07270	pK18 <i>mobsacB</i> with a 1.5-kb HindIII-XbaI carrying SLG_07270 from pKS0727	This study
pKmb07270K	pKmb07270 with a 1.3-kb EcoRV fragment carrying <i>kan</i> from pIK03 into NruI site of SLG_07270	This study
pAK20400	pAK405 with a 2.3-kb deletion cassette carrying up- and downstream regions of SLG_20400	This study
pE16FA	pET-16b with a 2.2-kb NdeI-BamHI fragment carrying <i>ferA</i>	31
pE16FB	pET-16b with a 0.9-kb NdeI-BamHI PCR amplified fragment carrying <i>ferB</i>	This study
pE16FB2	pET-16b with a 1.1-kb NdeI-BamHI PCR amplified fragment carrying <i>ferB2</i>	This study

<sup>a</sup>Km<sup>r</sup>, Nal<sup>r</sup>, Sm<sup>r</sup>, Ap<sup>r</sup>, Tc<sup>r</sup>, Cm<sup>r</sup>, and Cb<sup>r</sup>, resistance to kanamycin, nalidixic acid, streptomycin, ampicillin, tetracycline, chloramphenicol, and carbenicillin, respectively.

light-yellow solid (12.5 g, 32.7 mmol, 89%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  6.51 (s, 2H), 5.00 (dt,  $J$  = 9.0, 3.5 Hz, 1H), 4.13 (q,  $J$  = 7.0 Hz, 2H), 3.74 (s, 6H), 3.36 (m, 1H), 2.70 (dd,  $J$  = 16.0, 9.0 Hz, 1H), 2.63 (dd,  $J$  = 16.0, 3.5 Hz, 1H), 1.22 (t,  $J$  = 7.0 Hz, 3H), 0.97 (s, 9H), 0.08 (s, 6H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  172.4, 151.5, 135.2, 133.6, 102.5, 70.6, 60.8, 55.7, 43.7, 25.8, 18.7, 14.2, -4.7.

(iii) **Synthesis of 1-(4-(tert-butyldimethylsilyloxy)-3,5-dimethoxyphenyl)propane-1,3-diol (compound C).** A suspension of LiAlH<sub>4</sub> (1.4 g, 37.8 mmol, 2.2 eq) in THF (100 ml) was cooled to -20°C. After 15 min, a solution of compound B (6.6 g, 17.2 mmol, 1.0 eq) in THF (20 ml, overall  $c$  = 0.14 M) was added at -20°C, and the resulting mixture was left to stir at this temperature for 1 h. After the reaction had reached completion, it was poured slowly into a stirring mixture of ethyl acetate (300 ml) and saturated aqueous solution of Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (2  $\times$  300 ml). The organic layer was washed brine (300 ml), dried with MgSO<sub>4</sub>, filtered, and concentrated *in vacuo*. Purification by silica gel chromatography using 5 to 10% methanol in DCM afforded compound C as a colorless oil (5.62 g, 16.4 mmol, 96%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  6.49 (s, 2H), 4.79 (dd,  $J$  = 8.5, 3.5 Hz, m, 1H), 3.77 (m, 2H), 3.75 (s, 6H), 3.32 (s, 1H), 2.93 (s, 1H), 1.94 (dddd,  $J$  = 14.0, 8.5, 7.0, 5.0 Hz, 1H), 1.84 (ddt,  $J$  = 14.0, 5.5, 4.0 Hz, 1H), 0.98 (s, 9H), 0.09 (s, 6H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  151.6, 137.2, 133.5, 102.6, 74.6, 61.5, 55.8, 40.6, 25.9, 18.8, -4.6.

(iv) **Synthesis of 1-(4-(tert-butyldimethylsilyloxy)-3,5-dimethoxyphenyl)-3-hydroxypropan-1-one (compound D).** 2,3-Dichloro-5,6-dicyanobenzoquinone (DDQ) (4.1 g, 18.1 mmol, 1.05 eq) was added to a stirring solution of compound C (5.6 g, 16.4 mmol, 1.0 eq) in THF (160 ml,  $c$  = 0.10 M) at 22°C, and the resulting mixture was left to stir at this temperature for 12 h. Afterward, the reaction mixture was diluted with ethyl acetate (300 ml) and washed with saturated aqueous solution of Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (2  $\times$  300 ml). The organic layer was washed with water (300 ml) and brine (300 ml), dried with MgSO<sub>4</sub>, filtered, and concentrated *in vacuo*. Purification by silica gel chromatography using 2 to 5% methanol in DCM afforded compound D as a white solid (5.1 g, 14.9 mmol, 91%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  7.16 (s, 2H), 3.97 (app q,  $J$  = 5.5 Hz, 2H), 3.80 (s, 6H), 3.15 (t,  $J$  = 5.5 Hz, 2H), 3.01 (app t,  $J$  = 6.0 Hz, 1H), 0.97 (s, 9H), 0.11 (s, 6H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  199.1, 151.4, 139.9, 129.4, 105.6, 58.3, 55.8, 40.0, 25.7, 18.8, -4.6.

(v) **Synthesis of HPS.** Tetrabutylammonium fluoride (TBAF; 1.0 M in THF, 8.8 ml, 8.8 mmol, 3.0 eq) was added to a stirring solution of compound D (1.0 g, 2.9 mmol, 1.0 eq) in THF (15 ml,  $c$  = 0.20 M) at




FIG 7 Synthetic routes to HPS and HPV.

22°C, and the resulting mixture was left to stir at this temperature for 1 h. Afterward, the reaction mixture was diluted with ethyl acetate (300 ml) and washed with saturated aqueous solution of NH<sub>4</sub>Cl (2 × 300 ml). The organic layer was washed with water (300 ml) and brine (300 ml), dried with MgSO<sub>4</sub>, filtered, and concentrated *in vacuo*. The crude material was recrystallized in petroleum ether and washed with a minimum amount of ethyl acetate to afford compound HPS as a white solid (0.5 g, 2.3 mmol, 77%). Spectroscopic data agreed with those reported previously (30). High-resolution MS [M – H]<sup>+</sup> calculated. For C<sub>11</sub>H<sub>13</sub>O<sub>5</sub> 225.0800; found 225.0766; <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 9.34 (s, 1H), 7.24 (s, 2H), 4.59 (s, 1H), 3.83 (s, 6H), 3.77 (t, *J* = 6.5 Hz, 2H), 3.10 (t, *J* = 6.5 Hz, 2H); <sup>13</sup>C NMR (125 MHz, DMSO-*d*<sub>6</sub>) δ 197.4, 147.6, 140.8, 127.5, 106.0, 57.3, 56.1, 41.0.

**Synthesis of HPV (G-Hibbert-Westwood-Lancefield ketone).** (i) **Synthesis of 4-((tert-butyl-dimethylsilyloxy)-3-methoxybenzaldehyde (compound E).** Compound E was synthesized using the same experimental procedure as that described for the synthesis of compound A. To vanillin (19.2 g, 126.0 mmol, 1.0 eq) in DCM (500 ml, *c* = 0.25 M) was added 4-DMAP (15.4 g, 126.0 mmol, 1.0 eq), imidazole (17.1 g, 252.0 mmol, 2.0 eq), and TBSCl (1.2 eq). Purification by silica gel chromatography using 5 to 10% ethyl acetate in petroleum ether afforded compound E as a colorless oil (30.0 g, 113.1 mmol, 90%). The spectroscopic data were in agreement with previously reported findings (55). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.73 (s, 1H), 7.27 (m, 2H), 6.85 (d, *J* = 8.0 Hz, 1H), 3.74 (s, 3H), 0.90 (s, 9H), 0.09 (s, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 190.5, 151.4, 151.0, 130.9, 125.8, 120.5, 110.0, 55.1, 25.4, 18.3, –4.78.

(ii) **Synthesis of ethyl 3-(4-((tert-butyl-dimethylsilyloxy)-3-methoxyphenyl)-3-hydroxypropanoate (compound F).** Compound F was synthesized using the same experimental procedure as that described for the synthesis of compound B. Compound E (10.9 g, 41.0 mmol, 1.0 eq) in THF (140 ml, *c* = 0.29 M), LiHMDS (1.0 M in THF; 53.2 ml, 53.2 mmol, 1.3 eq), and ethyl acetate (4.7 g, 53.2, 1.3 eq) were combined. Purification by silica gel chromatography using 10 to 30% ethyl acetate in petroleum ether afforded compound F as a light-yellow oil (11.9 g, 33.6 mmol, 81%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 6.84 (d, *J* = 1.5 Hz, 1H), 6.72 (m, 2H), 4.98 (dt, *J* = 5.0, 3.5 Hz, 1H), 4.09 (q, *J* = 7.0 Hz, 2H), 3.73 (s, 3H), 3.50 (m, 1H), 2.68 (dd, *J* = 16.0, 9.5 Hz, 1H), 2.59 (dd, *J* = 16.0, 4.0 Hz, 1H), 1.18 (t, *J* = 7.0 Hz, 3H), 0.95 (s, 9H), 0.09 (s, 6H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.3, 150.9, 144.4, 136.3, 120.6, 118.0, 109.5, 70.2, 60.7, 55.3, 43.6, 25.7, 18.4, 14.1, –4.7.

(iii) **Synthesis of 1-(4-((tert-butyl-dimethylsilyloxy)-3-methoxyphenyl)propane-1,3-diol (compound G).** Compound G was synthesized using the same experimental procedure as that described for the synthesis of compound C. LiAlH<sub>4</sub> (1.6 g, 40.1 mmol, 2.2 eq) in THF (80 ml) and compound F (6.6 g, 18.6 mmol, 1.0 eq) in THF (20 ml, overall *c* = 0.18 M) were combined. Purification by silica gel chromatography using 5 to 10% methanol in DCM afforded compound G as a light-yellow oil (5.4 g, 17.4 mmol, 94%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 6.89 (d, *J* = 1.5 Hz, 1H), 6.80 (m, 2H), 4.86 (m, 1H), 3.81 (s, 3H), 3.23 (s, 1H), 2.88 (s, 1H), 2.00 (m, 1H), 1.88 (m, 1H), 1.01 (s, 9H), 0.16 (s, 6H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 151.0, 144.4, 138.1, 120.8, 118.1, 109.6, 74.3, 61.5, 55.6, 40.6, 25.8, 18.6, –4.5.

(iv) **Synthesis of 1-(4-((tert-butyl-dimethylsilyloxy)-3-methoxyphenyl)-3-hydroxypropan-1-one (compound H).** Compound H was synthesized using the same experimental procedure as that described for the synthesis of compound D. DDQ (4.3 g, 19.2 mmol, 1.05 eq) and compound G (5.4 g, 17.4 mmol, 1.0 eq) in THF (170 ml, *c* = 0.10 M) were combined. Purification by silica gel chromatography using 2 to 5% methanol in DCM afforded compound H as a light-yellow oil (4.1 g, 13.3 mmol, 76%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.43 to 7.35 (m, 2H), 6.82 (d, *J* = 8.0 Hz, 1H), 3.95 (t, *J* = 5.5 Hz, 2H), 3.79 (s, 3H), 3.12 (t, *J* = 5.5 Hz, 2H), 0.94 (s, 9H), 0.13 (s, 6H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 199.1, 151.1, 150.4, 130.8, 122.7, 120.3, 110.9, 58.2, 55.4, 40.0, 25.6, 18.5, –4.6.

(v) **Synthesis of HPV.** HPV was synthesized using the same experimental procedure as that described for the synthesis of HPS. TBAF (1.0 M in THF; 15.6 ml, 15.6 mmol, 1.2 eq) and compound H (4.13 g, 13.3 mmol, 1.0 eq) in THF (100 ml, *c* = 0.13 M) were combined. Purification by silica gel chromatography afforded HPV as a white solid (1.0 g, 5.1 mmol, 38%). Spectroscopic analysis was in agreement with the reference (30). High-resolution MS [M + Na]<sup>+</sup> calculated. For C<sub>10</sub>H<sub>12</sub>O<sub>4</sub>Na 196.0700; found 196.0625; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.58 to 7.50 (m, 2H), 6.95 (d, *J* = 8.0 Hz, 1H), 6.12 (s, 1H), 4.01 (q, *J* = 5.0 Hz, 2H), 3.95 (s, 3H), 3.18 (t, *J* = 5.0 Hz, 2H), 2.73 (app t, *J* = 5.9 Hz, 1H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 199.2, 151.0, 146.9, 129.7, 123.8, 114.1, 109.7, 58.5, 56.2, 39.9.

**Preparation of other substrates.** MPHVP, DCA, and DCA-C were prepared as described previously (50, 56). For preparation of VAA, HPV was added into 15 ml of the cell suspensions of *hpvZ*-expressing *E. coli* cells (optical density at 600 nm [OD<sub>600</sub>] of 10.0) and SLG\_20400-expressing *E. coli* cells (OD<sub>600</sub> of 2.0) to a final concentration of 200 μM. After incubation with shaking for 12 h at 30°C, the culture was centrifuged, and the supernatant was filtered using an Amicon Ultraspinn filter unit (3-kDa cutoff; Millipore). The resulting filtrate was used as a preparation of 200 μM VAA. For the preparation of VAL-Tris, HPV was added to 15 ml of the cell suspension of *S. sanguinis* IAM 12578 harboring pJB12830 cells (OD<sub>600</sub> of 1.0) to a final concentration of 1 mM. After incubation with shaking for 45 h at 30°C, the culture was centrifuged, and the supernatant was collected. The supernatant was extracted with ethyl acetate, and then the extract was finally dissolved in the dimethyl sulfoxide. The compounds obtained were analyzed by HPLC-MS. Other aromatic compounds were purchased from Tokyo Chemical Ind., Co., Ltd.; Sigma-Aldrich Co., LLC; and Wako Pure Chemical Ind., Ltd.

**Preparation of resting cells and cell extracts and fractionation of cell extracts.** Cells of SYK-6 and its mutants grown in Wx-SEMP for 16 h or LB for 24 h were collected by centrifugation (5,000 × *g* for 5 min) and then washed twice with 50 mM Tris-HCl buffer (pH 7.5; buffer A). The cells were resuspended in the same buffer and used as resting cells. Cells were broken by an ultrasonic disintegrator (57), and the supernatants of cell lysates were obtained as cell extracts after centrifugation (19,000 × *g* for 15 min). To examine the cofactor requirements, cell extracts were filtered using an Amicon Ultraspinn filter unit



(10-kDa cutoff; Millipore) and then washed five times buffer with buffer A. The filtrates were used as cell extracts (>10 kDa). For fractionation of cell extracts, they were further centrifuged at  $124,000 \times g$  for 30 min at 4°C, and the resulting supernatants were used as the soluble fraction. The pellets were washed twice with buffer A, resuspended in the same buffer, and used as the membrane fraction.

**Identification of the metabolites.** SYK-6 resting cells ( $OD_{600}$  of 5.0) were incubated with 1 mM HPV or HPS in buffer A at 30°C with shaking. SME077 resting cells ( $OD_{600}$  of 0.5 or 5.0) were incubated with 100  $\mu$ M VAA or 1 mM ferulate in buffer A at 30°C with shaking. After incubation, portions of the reaction mixtures were collected, and reactions were stopped by centrifugation. Methanol was added to the resulting supernatants (final concentration, 40%), and the filtered samples were analyzed by HPLC-MS.

SYK-6 cell extracts (>10 kDa; 500  $\mu$ g protein/ml) were incubated with 200  $\mu$ M HPV or HPS in the presence or absence of 500  $\mu$ M  $NAD^+$  or 500  $\mu$ M  $NAD^+$ , 2 mM CoA, 2.5 mM  $MgSO_4$ , and 2.5 mM ATP in buffer A at 30°C. SME077 cell extracts (>10 kDa; 500  $\mu$ g of protein/ml) were incubated with 100  $\mu$ M VAA in the presence of 1 mM CoA, 1.25 mM  $MgSO_4$ , and 1.25 mM ATP in buffer A at 30°C. The reactions were stopped by the addition of methanol or acetonitrile (final concentration, 50%) at various sampling time points. Precipitated proteins were removed by centrifugation at  $19,000 \times g$  for 15 min. The resulting supernatants of the reaction mixtures were analyzed by HPLC-MS.

**Enzyme assays using cell extracts of SYK-6.** The HPV-oxidizing activities of SYK-6 cell extracts were determined by measuring the decrease in the amount of HPV by HPLC analysis. In order to examine the effect of GGE on enzyme induction, SYK-6 cells grown in LB were inoculated into Wx-SEMP to an  $OD_{600}$  of 0.2 and grown at 30°C. GGE (5 mM) was added when the  $OD_{600}$  of the culture reached 0.5, and the culture was then further incubated for 12 h. SYK-6 cell extracts (500  $\mu$ g of protein/ml) were incubated with 200  $\mu$ M HPV in the presence or absence of cofactors (500  $\mu$ M PMS, 500  $\mu$ M FAD + PMS, or 500  $\mu$ M  $NAD^+$ ) in buffer A for 30 min at 30°C. The reaction mixtures were analyzed by HPLC, and HPV was detected at 276 nm. The specific activity was expressed in moles of HPV converted per min per mg of protein.

In order to examine the activity of VAL-oxidizing activity, the production of VAA from HPV was measured when HPV was reacted with SYK-6 cell extracts (>10 kDa). The cell extracts (>10 kDa; 500  $\mu$ g of protein/ml) were incubated with HPV in the presence of cofactors (500  $\mu$ M FAD, 500  $\mu$ M  $NAD^+$ , or 500  $\mu$ M  $NADP^+$ ) in buffer A for 2 h at 30°C. The supernatant of the reaction mixtures was analyzed by HPLC, and compounds were detected at 280 nm.

**Analytical methods.** HPLC-MS analysis was performed with the Acquity UPLC system (Waters) coupled with an Acquity TQ detector as described previously (58). Reaction products of HPV, coniferyl alcohol, sinapyl alcohol, cinnamyl alcohol, 3-(4-hydroxyphenyl)-1-propanol, homovanillyl alcohol, vanillyl alcohol, GGE, MPHPV, DCA, and DCA-C were analyzed using a TSKgel ODS-140HTP column (2.1 by 100 mm; Tosoh). Reaction products of HPS were analyzed using an Acquity UPLC BEH  $C_{18}$  column (2.1 by 100 mm; Waters). Reaction products of VAA were analyzed using both columns. All analyses were carried out at a flow rate of 0.5 ml/min. The mobile phase was a mixture of solution A (acetonitrile containing 0.1% formic acid) and solution B (water containing 0.1% formic acid) under the following conditions: (i) detection of the reaction products of HPV: 0 to 4.2 min, 5% A; 4.2 to 6.0 min, linear gradient from 5 to 30% A; 6.0 to 6.5 min, decreasing gradient from 30 to 5% A; 6.5 to 7.0 min, 5% A; (ii) detection of VAL generated from HPV: 0 to 4.7 min, 5% A; 4.7 to 4.9 min, linear gradient from 5 to 80%; 4.9 to 7.0 min, 80% A; (iii) detection of VAA-CoA generated from VAA: 0 to 0.8 min, 10% A; 0.8 to 1.0 min, linear gradient from 10 to 25% A; 1.0 to 1.5 min, 25% A; 1.5 to 1.8 min, decreasing gradient from 25 to 10% A; 1.8 to 3.0 min, 10% A; (iv) detection of vanillate generated from VAA: 0 to 3.0 min, linear gradient from 5 to 15% A; 3.0 to 4.0 min, decreasing gradient from 15 to 5%; (v) detection of the reaction product of vanillyl alcohol: 0 to 5.0 min, 5% A; (vi) detection of the reaction products of coniferyl alcohol, sinapyl alcohol, cinnamyl alcohol, homovanillyl alcohol, and HPS: 0 to 7.0 min, 10% A; (vii) detection of the reaction products of 3-(4-hydroxyphenyl)-1-propanol, GGE, and ferulate: 0 to 5.0 min, 15% A; and (viii) detection of the reaction products of MPHPV, DCA, and DCA-C: 0 to 5.0 min, 25% A. HPV, HPS, VAL, VAL-Tris, VAA, VAA-CoA, vanillate, syringate, acetovanillone, coniferyl alcohol, sinapyl alcohol, cinnamyl alcohol, 3-(4-hydroxyphenyl)-1-propanol, homovanillyl alcohol, vanillyl alcohol, GGE, MPHPV, DCA, and DCA-C were detected at 276, 300, 310, 352, 280, 300, 260, 276, 275, 263, 273, 250, 276, 279, 279, 277, 280, 277, and 326 nm, respectively. In ESI-MS analysis, MS spectra were obtained using the positive- and negative-ion modes with the settings described in our previous study (58). Protein concentrations were determined by the Bradford method using the Bio-Rad protein assay kit or by using Lowry's assay with a DC protein assay kit (Bio-Rad Laboratories). The expression of the genes was analyzed by SDS-PAGE. Protein bands in gels were stained with Coomassie brilliant blue.

**DNA manipulations and sequence analysis.** The PCR primers used in this study are listed in Table 3. Nucleotide sequences were determined using a CEQ 2000XL genetic analysis system (Beckman Coulter). Sequence analysis was performed with the MacVector program (MacVector, Inc.). Sequence similarity searches, pairwise alignments, and multiple alignments were carried out using the BLASTP program (59), the EMBOSS Needle program through the EMBL-EBI server (60), and the Clustal Omega program (61), respectively.

**Cloning of *hvpZ*.** A partially Sall-digested gene library of SYK-6 constructed with pVK100 was introduced into a host strain, *S. sanguinis* IAM 12578, by triparental mating (62). The ability of 1,000 transconjugants grown in diluted LB to transform 15  $\mu$ M HPV was analyzed by HPLC. Southern hybridization analysis of the Sall digests of positive clones with pSA53 as a probe was carried out using the digoxigenin system (Roche Diagnostics). The hybridized Sall fragments were cloned in pBluescript II SK(+), and the nucleotide sequences of both ends of the inserts were determined.

**TABLE 3** Primer sequences used for construction of plasmids and colony PCR

Plasmid or strain	Primer	Sequence (5'-3')
Plasmids		
pT7B12830	12830_pT7B_F	AGACAGGCATATGGTTGATG
	12830_pT7B_R	GGGCGGCATGGATCCGC
pAK20400	dis20400_Top_F	CGGTACCCGGGATCCGGCTTCGGTGACAATCAT
	dis20400_Top_R	ATGTCCGTGGTGTCTGCGT
	dis20400_Bot_F	ACGCAGAACACCACGGACATTCCTCCCCGTGATGACCTAT
pE16FB	dis20400_Bot_R	CGACTCTAGAGGATCGTGCGGCATCAACATATCG
	ferB_exp_F	GGAAAATCATATGTCCGAGG
pE16FB2	ferB_exp_R	ATACTGGCGGATCCAGCC
	ferB2_exp_F	TGAGGATGCATATGTCCGGATG
Colony PCR (strain)	ferB2_exp_R	GCCGGATCCCGGAATGC
	dis20400_conf_F	CCTTCATGCCATCATAAAT
SME061	dis20400_Bot_R	CGACTCTAGAGGATCGTGCGGCATCAACATATCG

**Expression of SYK-6 genes in *E. coli* and SYK-6.** A DNA fragment carrying *hvpZ* was amplified by PCR using SYK-6 total DNA as a template. The amplified fragment was ligated into pT7Blue, and the NdeI-BamHI fragment of the resulting plasmid was then inserted in pCold I to generate pCold12830. DNA fragments carrying *ferB* and *ferB2* were amplified by PCR. The amplified fragments were ligated into pET-16b to obtain pE16FB and pE16FB2. Nucleotide sequences of their inserts were confirmed by nucleotide sequencing. Expression plasmids for SYK-6 ALDH genes and *ferA* were prepared in previous studies (31, 51). The expression plasmids were introduced into *E. coli* BL21(DE3), and the transformed cells were grown in LB. In the case of *hvpZ* expression, pTf16 encoding the trigger factor chaperone was introduced into *E. coli* BL21(DE3) in addition to pCold12830, and the resulting transformant was grown in the presence of 0.5 mg/ml L-arabinose. The expressions of *hvpZ* and other genes were induced for 24 h at 16°C and for 4 h at 30°C, respectively, by adding 0.1 to 1 mM isopropyl- $\beta$ -D-thiogalactopyranoside when the OD<sub>600</sub> of the cultures reached 0.5. Cells were then harvested by centrifugation and washed with buffer A. pJB12830 was created by inserting the 2.3-kb BamHI-SacII (blunted) fragment carrying *hvpZ* from pBH37F into pJB864. pJB12830 was introduced into SYK-6, and the transformed cells were grown in LB containing 1 mM *m*-toluate for 24 h. Resting cells and cell extracts were prepared as described above.

**Construction of mutants.** To construct pKmb12830K, the 1.3-kb Sall-BamHI fragment carrying the kanamycin resistance gene (*kan*) of pK03 was inserted into the XhoI-BglII sites in *hvpZ* of pUC12830. The 3.1-kb Sall fragment of the resulting plasmid was ligated into the same site of pK19*mobsacB* to obtain pKmb12830K. To construct pKmb07270K, the 1.5-kb HindIII-XbaI fragment of pKS0727 was ligated into the same sites of pK19*mobsacB*, yielding pKmb07270. pKmb07270K was constructed by inserting *kan* into the NruI site in SLG\_07270 of pKmb07270. pKmb12830K and pKmb07270K were independently introduced into SYK-6 cells by electroporation, and candidate mutants were isolated as described previously (63). Disruption of each gene was examined by Southern hybridization analysis (see Fig. S3 in the supplemental material). To construct pAK20400, upstream and downstream regions (ca. 1.0 kb each) of SLG\_20400 were amplified by PCR. The resulting fragments were cloned into pAK405 by In-Fusion cloning (In-Fusion HD cloning kit; TaKaRa Bio). pAK20400 was introduced into SYK-6 cells by triparental mating (62), and the mutant strain was selected as described previously (64). Disruption of the gene was confirmed by colony PCR. For the complementation of *hvpZ* in SME059, pJB12830 was introduced into cells by electroporation.

**Resting cell assays.** Resting cells of *E. coli* harboring pCold12830 and pTf16 (OD<sub>600</sub> of 10.0), SYK-6 (OD<sub>600</sub> of 0.5, 1.0, or 5.0), SYK-6 harboring pJB864 (OD<sub>600</sub> of 1.0), SME059 (OD<sub>600</sub> of 0.5, 1.0, or 5.0), SME059 harboring pJB864 (OD<sub>600</sub> of 1.0), SME059 harboring pJB12830 (OD<sub>600</sub> of 1.0), and SME009 (OD<sub>600</sub> of 1.0) prepared from LB-grown cultures were incubated with substrates (200  $\mu$ M HPV, 200  $\mu$ M HPS, 200  $\mu$ M GGE, or 100  $\mu$ M VAA) at 30°C with shaking. Portions of the cultures were collected, and the amounts of substrates were measured by HPLC.

**Enzyme properties of HpvZ.** To determine the cellular localization of HpvZ, the HPV-oxidizing activities of the soluble and membrane fractions prepared from cell extracts of SYK-6 were measured. The cell extracts (500  $\mu$ g of protein/ml), soluble fraction (500  $\mu$ g of protein/ml), and membrane fraction (500  $\mu$ g of protein/ml) were incubated with 200  $\mu$ M HPV and 500  $\mu$ M PMS in buffer A for 10 or 30 min at 30°C. The amounts of HPV were measured by HPLC.

The enzyme reaction was typically carried out by incubating the membrane fraction (300  $\mu$ g of protein/ml) of *E. coli* cells harboring pCold12830 and pTf16 with 200  $\mu$ M HPV and 500  $\mu$ M PMS in buffer A for 10 min at 30°C. After incubation, the amount of substrate was measured by HPLC. The optimum pH was determined at pH ranges from 7.0 to 10.0 using 50 mM GTA buffer (50 mM 3,3-dimethylglutaric acid, 50 mM Tris, and 50 mM 2-amino-2-methyl-1,3-propanediol; pH 7.0 to 9.0) and 50 mM CHES (*N*-cyclohexyl-2-aminoethanesulfonic acid) buffer (pH 8.6 to 10) at 30°C. The optimum temperature was determined at temperature ranges from 25 to 50°C using buffer A. To determine the substrate range, 200  $\mu$ M HPV, HPS, coniferyl alcohol, sinapyl alcohol, cinnamyl alcohol, 3-(4-hydroxyphenyl)-1-propanol, homovanillyl alcohol, vanillyl alcohol, GGE, MHPV, DCA, and DCA-C were used for the reaction, and the

decrease in the amount of substrate was measured by HPLC. To examine the effect of flavin cofactors on HpvZ activity, the activities of HpvZ in the presence of 500  $\mu$ M FAD or flavin mononucleotide were determined. To examine the effect of ubiquinone derivatives on HpvZ activity, the activities of HpvZ in the presence of CoQ<sub>9</sub> and CoQ<sub>1</sub> were determined. The enzyme reactions were carried out by incubating membrane fractions of *E. coli* cells harboring pCold12830 and pTf16 (300  $\mu$ g of protein/ml) or SYK-6 cells harboring pJB12830 (300  $\mu$ g of protein/ml) with 200  $\mu$ M HPV and 500  $\mu$ M CoQ<sub>9</sub> or CoQ<sub>1</sub> in buffer A for 10 and 5 min, respectively, at 30°C. The decrease in the substrate was determined by HPLC analysis.

**Identification of the ALDH genes involved in VAL conversion.** The abilities of the 23 ALDHs of SYK-6 to convert VAL were examined by measuring the amount of VAA produced from HPV when HPV was reacted with both HpvZ and each ALDH. Resting cells of *E. coli* expressing each ALDH gene (OD<sub>600</sub> of 1.0) and *E. coli* harboring pCold12830 and pTf16 (OD<sub>600</sub> of 5.0 or 10.0) were incubated with 100  $\mu$ M HPV in buffer A at 30°C with shaking. Portions of the cultures were collected at various sampling time points, and the supernatants of the reaction mixtures were analyzed by HPLC.

The mixtures of resting cells of SYK-6, SME031, SME045, SME061, or SME092 (OD<sub>600</sub> of 0.5) and resting cells of *E. coli* harboring pCold12830 and pTf16 (OD<sub>600</sub> of 10.0) were incubated with 1 mM HPV in buffer A at 30°C with shaking. Portions of the reaction mixtures were collected at various sampling time points. The supernatants prepared were analyzed by HPLC.

**Conversion of VAA by enzymes for ferulate catabolism.** Crude enzymes of FerA, FerB, and FerB2 were prepared from the *E. coli* transformants described above. FerA, FerA + FerB, and FerA + FerB2 (100  $\mu$ g protein/ml of each) were incubated with 100  $\mu$ M VAA, 1 mM CoA, 1.25 mM MgSO<sub>4</sub>, and 1.25 mM ATP in buffer A for 60 min at 30°C. The supernatants prepared were analyzed by HPLC.

## SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at <https://doi.org/10.1128/AEM.02670-17>.

**SUPPLEMENTAL FILE 1**, PDF file, 2.4 MB.

## ACKNOWLEDGMENTS

We thank Daisuke Sato for assistance with the construction of mutants. We also thank Daniel Miles-Barrett and Amol Thakkar for their contributions.

This study was supported in part by a grant from the JSPS KAKENHI (grant 26850046) and the Japan Science and Technology Agency (Advanced Low Carbon Technology Research and Development Program).

## REFERENCES

- Boerjan W, Ralph J, Baucher M. 2003. Lignin biosynthesis. *Annu Rev Plant Biol* 54:519–546. <https://doi.org/10.1146/annurev.arplant.54.031902.134938>.
- Ralph J, Lundquist K, Brunow G, Lu F, Kim H, Schatz PF, Marita JM, Hatfield RD, Ralph SA, Christensen JH, Boerjan W. 2004. Lignins: natural polymers from oxidative coupling of 4-hydroxyphenyl-propanoids. *Phytochem Rev* 3:29–60. <https://doi.org/10.1023/B:PHYT.0000047809.65444.a4>.
- Doherty WOS, Mousavioun P, Fellows CM. 2011. Value-adding to cellulosic ethanol: lignin polymers. *Ind Crop Prod* 33:259–276. <https://doi.org/10.1016/j.indcrop.2010.10.022>.
- Zakzeski J, Buijninx PCA, Jongerius AL, Weckhuysen BM. 2010. The catalytic valorization of lignin for the production of renewable chemicals. *Chem Rev* 110:3552–3599. <https://doi.org/10.1021/cr900354u>.
- Otsuka Y, Nakamura M, Shigehara K, Sugimura K, Masai E, Ohara S, Katayama Y. 2006. Efficient production of 2-pyrone 4,6-dicarboxylic acid as a novel polymer-based material from protocatechuate by microbial function. *Appl Microbiol Biotechnol* 71:608–614. <https://doi.org/10.1007/s00253-005-0203-7>.
- Michinobu T, Bito M, Yamada Y, Tanimura M, Katayama Y, Masai E, Nakamura M, Otsuka Y, Ohara S, Shigehara K. 2009. Fusible, elastic, and biodegradable polyesters of 2-pyrone-4,6-dicarboxylic acid (PDC). *Polym J* 41:1111–1116. <https://doi.org/10.1295/polymj.PJ2009045R>.
- Michinobu T, Hiraki K, Inazawa Y, Katayama Y, Masai E, Nakamura M, Ohara S, Shigehara K. 2011. Click synthesis and adhesive properties of novel biomass-based polymers from lignin-derived stable metabolic intermediate. *Polym J* 43:648–653. <https://doi.org/10.1038/pj.2011.40>.
- Sonoki T, Morooka M, Sakamoto K, Otsuka Y, Nakamura M, Jellison J, Goodell B. 2014. Enhancement of protocatechuate decarboxylase activity for the effective production of muconate from lignin-related aromatic compounds. *J Biotechnol* 192 (Pt A):71–77. <https://doi.org/10.1016/j.jbiotec.2014.10.027>.
- Johnson CW, Salvachúa D, Khanna P, Smith H, Peterson DJ, Beckham GT. 2016. Enhancing muconic acid production from glucose and lignin-derived aromatic compounds via increased protocatechuate decarboxylase activity. *Metab Eng Commun* 3:111–119. <https://doi.org/10.1016/j.meten.2016.04.002>.
- Sonoki T, Takahashi K, Sugita H, Hatamura M, Azuma Y, Sato T, Suzuki S, Kamimura N, Masai E. 2018. Glucose-free *cis,cis*-muconic acid production via new metabolic designs corresponding to the heterogeneity of lignin. *ACS Sustainable Chem Eng* 6:1256–1264. <https://doi.org/10.1021/acssuschemeng.7b03597>.
- Linger JG, Vardon DR, Guarnieri MT, Karp EM, Hunsinger GB, Franden MA, Johnson CW, Chupka G, Strathmann TJ, Pienkos PT, Beckham GT. 2014. Lignin valorization through integrated biological funneling and chemical catalysis. *Proc Natl Acad Sci U S A* 111:12013–12018. <https://doi.org/10.1073/pnas.1410657111>.
- Akiyama T, Magara K, Matsumoto Y, Meshitsuka G, Ishizu A, Lundquist K. 2000. Proof of the presence of racemic forms of arylglycerol- $\beta$ -aryl ether structure in lignin: studies on the stereo structure of lignin by ozonation. *J Wood Sci* 46:414–415. <https://doi.org/10.1007/BF00776407>.
- Kamimura N, Takahashi K, Mori K, Araki T, Fujita M, Higuchi Y, Masai E. 2017. Bacterial catabolism of lignin-derived aromatics: new findings in a recent decade: update on bacterial lignin catabolism. *Environ Microbiol Rep* 9:679–705. <https://doi.org/10.1111/1758-2229.12597>.
- Sato Y, Moriuchi H, Hishiyama S, Otsuka Y, Oshima K, Kasai D, Nakamura M, Ohara S, Katayama Y, Fukuda M, Masai E. 2009. Identification of three alcohol dehydrogenase genes involved in the stereospecific catabolism of arylglycerol- $\beta$ -aryl ether by *Sphingobium* sp. strain SYK-6. *Appl Environ Microbiol* 75:5195–5201. <https://doi.org/10.1128/AEM.00880-09>.
- Masai E, Ichimura A, Sato Y, Miyauchi K, Katayama Y, Fukuda M. 2003. Roles of the enantioselective glutathione *S*-transferases in cleavage of  $\beta$ -aryl ether. *J Bacteriol* 185:1768–1775. <https://doi.org/10.1128/JB.185.6.1768-1775.2003>.
- Tanamura K, Abe T, Kamimura N, Kasai D, Hishiyama S, Otsuka Y, Nakamura M, Kajita S, Katayama Y, Fukuda M, Masai E. 2011. Character-

- ization of the third glutathione *S*-transferase gene involved in enantioselective cleavage of the  $\beta$ -aryl ether by *Sphingobium* sp. strain SYK-6. *Biosci Biotechnol Biochem* 75:2404–2407. <https://doi.org/10.1271/bbb.110525>.
17. Meux E, Prosper P, Masai E, Mulliert G, Dumarçay S, Morel M, Didierjean C, Gelhaye E, Favier F. 2012. *Sphingobium* sp. SYK-6 LigG involved in lignin degradation is structurally and biochemically related to the glutathione transferase omega class. *FEBS Lett* 586:3944–3950. <https://doi.org/10.1016/j.febslet.2012.09.036>.
  18. Pereira JH, Heins RA, Gall DL, McAndrew RP, Deng K, Holland KC, Donohue TJ, Noguera DR, Simmons BA, Sale KL, Ralph J, Adams PD. 2016. Structural and biochemical characterization of the early and late enzymes in the lignin  $\beta$ -aryl ether cleavage pathway from *Sphingobium* sp. SYK-6. *J Biol Chem* 291:10228–10238. <https://doi.org/10.1074/jbc.M115.700427>.
  19. Reiter J, Strittmatter H, Wiemann LO, Schieder D, Sieber V. 2013. Enzymatic cleavage of lignin  $\beta$ -O-4 aryl ether bonds via net internal hydrogen transfer. *Green Chem* 15:1373–1381. <https://doi.org/10.1039/c3gc40295a>.
  20. Gall DL, Kim H, Lu F, Donohue TJ, Noguera DR, Ralph J. 2014. Stereochemical features of glutathione-dependent enzymes in the *Sphingobium* sp. strain SYK-6  $\beta$ -aryl etherase pathway. *J Biol Chem* 289:8656–8667. <https://doi.org/10.1074/jbc.M113.536250>.
  21. Gall DL, Ralph J, Donohue TJ, Noguera DR. 2014. A group of sequence-related sphingomonad enzymes catalyzes cleavage of  $\beta$ -aryl ether linkages in lignin  $\beta$ -guaiacyl and  $\beta$ -syringyl ether dimers. *Environ Sci Technol* 48:12454–12463. <https://doi.org/10.1021/es503886d>.
  22. Picart P, Müller C, Mottweiler J, Wiermans L, Bolm C, de Maria PD, Schallmey A. 2014. From gene towards selective biomass valorization: bacterial  $\beta$ -etherases with catalytic activity on lignin-like polymers. *ChemSusChem* 7:3164–3171. <https://doi.org/10.1002/cssc.201402465>.
  23. Ohta Y, Nishi S, Hasegawa R, Hatada Y. 2015. Combination of six enzymes of a marine *Novosphingobium* converts the stereoisomers of  $\beta$ -O-4 lignin model dimers into the respective monomers. *Sci Rep* 5:15105. <https://doi.org/10.1038/srep15105>.
  24. Palamuru S, Dellas N, Pearce SL, Warden AC, Oakeshott JG, Pandey G. 2015. Phylogenetic and kinetic characterization of a suite of dehydrogenases from a newly isolated bacterium, strain SG61-1L, that catalyze the turnover of guaiacylglycerol- $\beta$ -guaiacyl ether stereoisomers. *Appl Environ Microbiol* 81:8164–8176. <https://doi.org/10.1128/AEM.01573-15>.
  25. Picart P, Sevenich M, de Maria PD, Schallmey A. 2015. Exploring glutathione lyases as biocatalysts: paving the way for enzymatic lignin depolymerization and future stereoselective applications. *Green Chem* 17:4931–4940. <https://doi.org/10.1039/C5GC01078K>.
  26. Helmich KE, Pereira JH, Gall DL, Heins RA, McAndrew RP, Bingman C, Deng K, Holland KC, Noguera DR, Simmons BA, Sale KL, Ralph J, Donohue TJ, Adams PD, Phillips GN, Jr. 2016. Structural basis of stereospecificity in the bacterial enzymatic cleavage of  $\beta$ -aryl ether bonds in lignin. *J Biol Chem* 291:5234–5246. <https://doi.org/10.1074/jbc.M115.694307>.
  27. Ohta Y, Hasegawa R, Kurosawa K, Maeda AH, Koizumi T, Nishimura H, Okada H, Qu C, Saito K, Watanabe T, Hatada Y. 2017. Enzymatic specific production and chemical functionalization of phenylpropanone platform monomers from lignin. *ChemSusChem* 10:425–433. <https://doi.org/10.1002/cssc.201601235>.
  28. Rosini E, Allegretti C, Melis R, Cerioli L, Conti G, Pollegioni L, D'Arrigo P. 2016. Cascade enzymatic cleavage of the  $\beta$ -O-4 linkage in a lignin model compound. *Catal Sci Technol* 6:2195–2205. <https://doi.org/10.1039/C5CY01591J>.
  29. Higuchi Y, Takahashi K, Kamimura N, Masai E. 2018. Bacterial enzymes for the cleavage of lignin  $\beta$ -aryl ether bonds: properties and applications. In Beckham GT (ed), *Lignin valorization: emerging approaches*, in press. Royal Society of Chemistry, London, United Kingdom.
  30. Lancefield CS, Ojo OS, Tran F, Westwood NJ. 2015. Isolation of functionalized phenolic monomers through selective oxidation and C-O bond cleavage of the  $\beta$ -O-4 linkages in lignin. *Angew Chem Int Ed Engl* 54:258–262. <https://doi.org/10.1002/anie.201409408>.
  31. Kasai D, Kamimura N, Tani K, Umeda S, Abe T, Fukuda M, Masai E. 2012. Characterization of FerC, a MarR-type transcriptional regulator, involved in transcriptional regulation of the ferulate catabolic operon in *Sphingobium* sp. strain SYK-6. *FEMS Microbiol Lett* 332:68–75. <https://doi.org/10.1111/j.1574-6968.2012.02576.x>.
  32. Bubb WA, Berthon HA, Kuchel PW. 1995. Tris buffer reactivity with low-molecular-weight aldehydes: NMR characterization of the reactions of glyceraldehyde-3-phosphate. *Bioorg Chem* 23:119–130. <https://doi.org/10.1006/bioo.1995.1010>.
  33. Fukuzumi T, Oyake S, Matsumoto H. 1974. Synthesis of vanilloyl acetaldehyde. *Mokuzai Gakkaishi* 20:138–142.
  34. Niwa M, Saburi Y. 2002. Vanilloyl acetic acid as an unstable intermediate from  $\beta$ -hydroxypropiovanillone to acetovanillone. *Holzforschung* 56:360–362. <https://doi.org/10.1515/HF.2002.057>.
  35. Overhage J, Priefert H, Steinbüchel A. 1999. Biochemical and genetic analyses of ferulic acid catabolism in *Pseudomonas* sp. strain HR199. *Appl Environ Microbiol* 65:4837–4847.
  36. Masai E, Harada K, Peng X, Kitayama H, Katayama Y, Fukuda M. 2002. Cloning and characterization of the ferulic acid catabolic genes of *Sphingomonas paucimobilis* SYK-6. *Appl Environ Microbiol* 68:4416–4424. <https://doi.org/10.1128/AEM.68.9.4416-4424.2002>.
  37. Otani H, Lee YE, Casabon I, Eltis LD. 2014. Characterization of *p*-hydroxycinnamate catabolism in a soil actinobacterium. *J Bacteriol* 196:4293–4303. <https://doi.org/10.1128/JB.02247-14>.
  38. Campillo T, Renoud S, Kerzaon I, Vial L, Baude J, Gaillard V, Bellvert F, Chamignon C, Comte G, Nesme X, Lavire C, Hommais F. 2014. Analysis of hydroxycinnamic acid degradation in *Agrobacterium fabrum* reveals a coenzyme A-dependent, beta-oxidative deacetylation pathway. *Appl Environ Microbiol* 80:3341–3349. <https://doi.org/10.1128/AEM.00475-14>.
  39. Kallscheuer N, Vogt M, Kappelmann J, Krumbach K, Noack S, Bott M, Marienhagen J. 2016. Identification of the *phd* gene cluster responsible for phenylpropanoid utilization in *Corynebacterium glutamicum*. *Appl Microbiol Biotechnol* 100:1871–1881. <https://doi.org/10.1007/s00253-015-7165-1>.
  40. Takahashi K, Hirose Y, Kamimura N, Hishiyama S, Hara H, Araki T, Kasai D, Kajita S, Katayama Y, Fukuda M, Masai E. 2015. Membrane-associated glucose-methanol-choline oxidoreductase family enzymes PhcC and PhcD are essential for enantioselective catabolism of dehydrodiconiferyl alcohol. *Appl Environ Microbiol* 81:8022–8036. <https://doi.org/10.1128/AEM.02391-15>.
  41. Kirmair L, Skerra A. 2014. Biochemical analysis of recombinant AlkJ from *Pseudomonas putida* reveals a membrane-associated, flavin adenine dinucleotide-dependent dehydrogenase suitable for the biosynthetic production of aliphatic aldehydes. *Appl Environ Microbiol* 80:2468–2477. <https://doi.org/10.1128/AEM.04297-13>.
  42. Ohta T, Kawabata T, Nishikawa K, Tani A, Kimbara K, Kawai F. 2006. Analysis of amino acid residues involved in catalysis of polyethylene glycol dehydrogenase from *Sphingopyxis terrae*, using three-dimensional molecular modeling-based kinetic characterization of mutants. *Appl Environ Microbiol* 72:4388–4396. <https://doi.org/10.1128/AEM.02174-05>.
  43. Kawai F, Kimura T, Fukaya M, Tani Y, Ogata K, Ueno T, Fukami H. 1978. Bacterial oxidation of polyethylene glycol. *Appl Environ Microbiol* 35:679–684.
  44. Matsushita K, Ameyama M. 1982. D-Glucose dehydrogenase from *Pseudomonas fluorescens*, membrane-bound. *Methods Enzymol* 89:149–154. [https://doi.org/10.1016/S0076-6879\(82\)89026-5](https://doi.org/10.1016/S0076-6879(82)89026-5).
  45. Romero E, Gadda G. 2014. Alcohol oxidation by flavoenzymes. *Biomol Concepts* 5:299–318. <https://doi.org/10.1515/bmc-2014-0016>.
  46. Guillén F, Martínez AT, Martínez MJ. 1992. Substrate specificity and properties of the aryl-alcohol oxidase from the ligninolytic fungus *Pleurotus eryngii*. *Eur J Biochem* 209:603–611. <https://doi.org/10.1111/j.1432-1033.1992.tb17326.x>.
  47. Dijkman WP, de Gonzalo G, Mattevi A, Fraaije MW. 2013. Flavoprotein oxidases: classification and applications. *Appl Microbiol Biotechnol* 97:5177–5188. <https://doi.org/10.1007/s00253-013-4925-7>.
  48. Quaye O, Lountos GT, Fan F, Orville AM, Gadda G. 2008. Role of Glu312 in binding and positioning of the substrate for the hydride transfer reaction in choline oxidase. *Biochemistry* 47:243–256. <https://doi.org/10.1021/bi7017943>.
  49. Tan TC, Spadiut O, Wongnate T, Sucharitakul J, Krondorfer I, Sygmund C, Haltrich D, Chaiyen P, Peterbauer CK, Divne C. 2013. The 1.6 Å crystal structure of pyranose dehydrogenase from *Agaricus meleagris* rationalizes substrate specificity and reveals a flavin intermediate. *PLoS One* 8:e53567. <https://doi.org/10.1371/journal.pone.0053567>.
  50. Takahashi K, Kamimura N, Hishiyama S, Hara H, Kasai D, Katayama Y, Fukuda M, Kajita S, Masai E. 2014. Characterization of the catabolic pathway for a phenylcoumaran-type lignin-derived biaryl in *Sphingobium* sp. strain SYK-6. *Biodegradation* 25:735–745. <https://doi.org/10.1007/s10532-014-9695-0>.
  51. Kamimura N, Goto T, Takahashi K, Kasai D, Otsuka Y, Nakamura M, Katayama Y, Fukuda M, Masai E. 2017. A bacterial aromatic aldehyde dehydrogenase critical for the efficient catabolism of syringaldehyde. *Sci Rep* 7:44422. <https://doi.org/10.1038/srep44422>.
  52. Achterholt S, Priefert H, Steinbüchel A. 1998. Purification and character-

- ization of the coniferyl aldehyde dehydrogenase from *Pseudomonas* sp. strain HR199 and molecular characterization of the gene. *J Bacteriol* 180:4387–4391.
53. Simon O, Klaiber I, Huber A, Pfannstiel J. 2014. Comprehensive proteome analysis of the response of *Pseudomonas putida* KT2440 to the flavor compound vanillin. *J Proteomics* 109:212–227. <https://doi.org/10.1016/j.jpropt.2014.07.006>.
54. Cushman M, Nagarathnam D, Gopal D, He HM, Lin CM, Hamel E. 1992. Synthesis and evaluation of analogues of (Z)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene as potential cytotoxic and antimetabolic agents. *J Med Chem* 35:2293–2306. <https://doi.org/10.1021/jm00090a021>.
55. Shirai T, Kumihashi K, Sakasai M, Kusuoku H, Shibuya Y, Ohuchi A. 2017. Identification of a novel TRPM8 agonist from nutmeg: a promising cooling compound. *ACS Med Chem Lett* 8:715–719. <https://doi.org/10.1021/acsmmedchemlett.7b00104>.
56. Hishiyama S, Otsuka Y, Nakamura M, Ohara S, Kajita S, Masai E, Katayama Y. 2012. Convenient synthesis of chiral lignin model compounds via optical resolution: four stereoisomers of guaiacylglycerol- $\beta$ -guaiacyl ether and both enantiomers of 3-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-2-(2-methoxyphenoxy)propan-1-one (erone). *Tetrahedron Lett* 53:842–845. <https://doi.org/10.1016/j.tetlet.2011.12.016>.
57. Fukuhara Y, Kamimura N, Nakajima M, Hishiyama S, Hara H, Kasai D, Tsuji Y, Narita-Yamada S, Nakamura S, Katano Y, Fujita N, Katayama Y, Fukuda M, Kajita S, Masai E. 2013. Discovery of pinoselin reductase genes in sphingomonads. *Enzyme Microb Technol* 52:38–43. <https://doi.org/10.1016/j.enzmictec.2012.10.004>.
58. Fukuhara Y, Inakazu K, Kodama N, Kamimura N, Kasai D, Katayama Y, Fukuda M, Masai E. 2010. Characterization of the isophthalate degradation genes of *Comamonas* sp. strain E6. *Appl Environ Microbiol* 76:519–527. <https://doi.org/10.1128/AEM.01270-09>.
59. Johnson M, Zaretskaya I, Raytselis Y, Merezukh Y, McGinnis S, Madden TL. 2008. NCBI BLAST: a better web interface. *Nucleic Acids Res* 36:W5–W9. <https://doi.org/10.1093/nar/gkn201>.
60. Li W, Cowley A, Uludag M, Gur T, McWilliam H, Squizzato S, Park YM, Buso N, Lopez R. 2015. The EMBL-EBI bioinformatics web and programmatic tools framework. *Nucleic Acids Res* 43:W580–W584. <https://doi.org/10.1093/nar/gkv279>.
61. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, Lopez R, McWilliam H, Remmert M, Söding J, Thompson JD, Higgins DG. 2011. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. *Mol Syst Biol* 7:539. <https://doi.org/10.1038/msb.2011.75>.
62. Ditta G, Stanfield S, Corbin D, Helinski DR. 1980. Broad host range DNA cloning system for gram-negative bacteria: construction of a gene bank of *Rhizobium meliloti*. *Proc Natl Acad Sci U S A* 77:7347–7351.
63. Masai E, Shinohara S, Hara H, Nishikawa S, Katayama Y, Fukuda M. 1999. Genetic and biochemical characterization of a 2-pyrone-4,6-dicarboxylic acid hydrolase involved in the protocatechuate 4,5-cleavage pathway of *Sphingomonas paucimobilis* SYK-6. *J Bacteriol* 181:55–62.
64. Kaczmarczyk A, Vorholt JA, Francez-Charlot A. 2012. Markerless gene deletion system for sphingomonads. *Appl Environ Microbiol* 78:3774–3777. <https://doi.org/10.1128/AEM.07347-11>.
65. Katayama Y, Nishikawa S, Nakamura M, Yano K, Yamasaki M, Morohoshi N, Haraguchi T. 1987. Cloning and expression of *Pseudomonas paucimobilis* SYK-6 genes involved in the degradation of vanillate and protocatechuate in *P. putida*. *Mokuzai Gakkaishi* 33:77–79.
66. Peng X, Masai E, Kasai D, Miyauchi K, Katayama Y, Fukuda M. 2005. A second 5-carboxyvanillate decarboxylase gene, *ligW2*, is important for lignin-related biphenyl catabolism in *Sphingomonas paucimobilis* SYK-6. *Appl Environ Microbiol* 71:5014–5021. <https://doi.org/10.1128/AEM.71.9.5014-5021.2005>.
67. Yamamoto Y, Kasai D, Kamimura N, Masai E. 2012. Isolation and characterization of *bzaA* and *bzaB* of *Sphingobium* sp. strain SYK-6, which encode aromatic aldehydes dehydrogenases with different substrate preferences. *Trans GIGAKU* 1:01009/01001–01006.
68. Takeuchi M, Kawai F, Shimada Y, Yokota A. 1993. Taxonomic study of polyethylene glycol-utilizing bacteria: emended description of the genus *Sphingomonas* and new descriptions of *Sphingomonas macrogoltabidus* sp. nov., *Sphingomonas sanguis* sp. nov., and *Sphingomonas terrae* sp. nov. *Syst Appl Microbiol* 16:227–238. [https://doi.org/10.1016/S0723-2020\(11\)80473-X](https://doi.org/10.1016/S0723-2020(11)80473-X).
69. Studier FW, Moffatt BA. 1986. Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. *J Mol Biol* 189:113–130. [https://doi.org/10.1016/0022-2836\(86\)90385-2](https://doi.org/10.1016/0022-2836(86)90385-2).
70. Bolivar F, Backman K. 1979. Plasmids of *Escherichia coli* as cloning vectors. *Methods Enzymol* 68:245–267. [https://doi.org/10.1016/0076-6879\(79\)68018-7](https://doi.org/10.1016/0076-6879(79)68018-7).
71. Figurski DH, Helinski DR. 1979. Replication of an origin-containing derivative of plasmid RK2 dependent on a plasmid function provided in *trans*. *Proc Natl Acad Sci U S A* 76:1648–1652.
72. Short JM, Fernandez JM, Sorge JA, Huse WD. 1988.  $\lambda$  ZAP: a bacteriophage  $\lambda$  expression vector with in vivo excision properties. *Nucleic Acids Res* 16:7583–7600. <https://doi.org/10.1093/nar/16.15.7583>.
73. Yanisch-Perron C, Vieira J, Messing J. 1985. Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. *Gene* 33:103–119. [https://doi.org/10.1016/0378-1119\(85\)90120-9](https://doi.org/10.1016/0378-1119(85)90120-9).
74. Schäfer A, Tauch A, Jäger W, Kalinowski J, Thierbach G, Pühler A. 1994. Small mobilizable multi-purpose cloning vectors derived from the *Escherichia coli* plasmids pK18 and pK19: selection of defined deletions in the chromosome of *Corynebacterium glutamicum*. *Gene* 145:69–73. [https://doi.org/10.1016/0378-1119\(94\)90324-7](https://doi.org/10.1016/0378-1119(94)90324-7).
75. Masai E, Sasaki M, Minakawa Y, Abe T, Sonoki T, Miyauchi K, Katayama Y, Fukuda M. 2004. A novel tetrahydrofolate-dependent O-demethylase gene is essential for growth of *Sphingomonas paucimobilis* SYK-6 with syringate. *J Bacteriol* 186:2757–2765. <https://doi.org/10.1128/JB.186.9.2757-2765.2004>.
76. Blatny JM, Brautaset T, Winther-Larsen HC, Karunakaran P, Valla S. 1997. Improved broad-host-range RK2 vectors useful for high and low regulated gene expression levels in gram-negative bacteria. *Plasmid* 38:35–51. <https://doi.org/10.1006/plas.1997.1294>.
77. Masai E, Yamamoto Y, Inoue T, Takamura K, Hara H, Kasai D, Katayama Y, Fukuda M. 2007. Characterization of *ligV* essential for catabolism of vanillin by *Sphingomonas paucimobilis* SYK-6. *Biosci Biotechnol Biochem* 71:2487–2492. <https://doi.org/10.1271/bbb.70267>.